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4CHAPTER ONE
HEUCOBACTER PYLORI INFECTION AND ASSOCIATED
DISEASES IN MAN
51.1 DISCOVERY AND NOMENCLATURE
Helicobacter pylori infection of the upper gastrointestinal mucosa is 
arguably the commonest chronic bacterial infection in man. The organism 
was first cultured in April 1982 in the Microbiology Department of the 
Royal Perth Hospital in Perth, Western Australia (Marshall et al 1984). It 
was initially called Campylobacter pyloridis but this was recognised to be 
grammatically incorrect and it was renamed Campylobacter pylori in 1987 
(Marshall et al 1987). Subsequent studies indicated that the ultrastructure 
and fatty acid com position of the bacterium  were d istinct from 
Campylobacter organisms (Goodwin et al 1985). Further studies of rRNA 
sequence showed clearly that the organism did not belong to the genus 
Campylobacter or any other previously reported genus (Romaniuk et al
1987). For this reason, a new genus name was created - Helicobacter and 
the organism called Helicobacter pylori (Goodwin et al 1989). The name 
Helicobacter was chosen to reflect the two morphological appearances of 
the organism, Helical in vivo but often rodlike in vitro. It was called 
Helicobacter pylori as the bacteria are found in most abundance in the 
pre-pyloric region of the stomach (Dick et al 1989).
1.2 MICROBIOLOGY
H. pylori is a gram negative organism measuring 2-4um in length and 
0.5-1.0um in diameter. It is a motile organism with 6-7 sheathed flagella 
(Jones 1985). H. pylori is a microaerophilic organism and requires to be 
cultured in vitro in a "microaerobic" atmosphere with a reduced oxygen 
content. If exposed for more than a short period of time to air with 21% 
oxygen, the organism dies (Skirrow 1990). H. pylori is a urease positive 
organism and indeed is remarkable on account of its high urease activity. 
This particular biochemical feature of H. pylori will be discussed more 
fully in the following Chapter.
61.3 EPIDEMIOLOGY
As already mentioned, H. pylori is one of the commonest infections in 
man. Its prevalence in the general community varies with age and 
between countries. In the United Kingdom, the prevalence approximately 
equals that of the age of the subject, being less than 10% in those under 10 
years and more than 50% in those more than 50 years of age (Jones et al
1986). The prevalence in the United States is similar to that of the United 
Kingdom (Graham et al 1988). In the developing world, the prevalence of 
H. pylori is much higher and the infection is acquired much earlier in life 
(Holcombe et al 1992). For example, in the Ivory Coast, more than 50% 
of children are infected before reaching the age of 10 years (Megraud 
1989). In spite of the high prevalence of the infection, very little is known 
about its mechanism of transmission.
1.4 THE NATURE OF THE INFECTION IN MAN
H. pylori infection is confined to gastric-type mucosa. The organism is 
found in most abundance in the antrum and, particularly, the pre-pyloric 
region of the stomach. It is also found in the mucosa of the body of the 
stomach. The infection is only found in the duodenum on patches of 
gastric metaplasia (Wyatt et al 1987). It has also been identified on islets 
of gastric metaplasia in Barret’s oesophagus (Pauli et al 1988), Meckel’s 
diverticulum (Morris et al 1989) and in the rectum (Dye et al 1990). The 
specificity of H. pylori for gastric-type mucosa is thought to relate to its 
attachment to specific glycolipid receptors found only on gastric epithelial 
cells (Lingwood et al 1989).
1.4.1
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The organism is found lying underneath the gastric mucus layer in 
close contact with the epithelial cells. It can usually be visualised on 
routine haematoxylin and eosin-stained biopsies, although a number of 
stains have been developed to aid its detection (Wyatt and Gray 1992). 
The W arthin-Starry Silver Stain (conventionally a technique for 
demonstrating spirochaetes in tissue sections) was used by Warren and 
Marshall in their original observation (Marshall et al 1987). It should be 
noted that none of the routine histochemical stains referred to above, is 
specific for H. pylori but instead only demonstrate the characteristic 
appearance of the organism. Strictly speaking, bacteria recognised only 
by histological methods should be referred to as "Helicobacter-like 
organisms" (Goodwin et al 1989).
ANTRAL GASTRITIS
H. pylori infection does not invade the gastric epithelium but does 
induce an inflammatory reaction in the underlying mucosa. The vast 
majority of subjects with H. pylori thus also have gastritis and H. pylori is 
now recognised as the major cause of gastritis in humans (Dixon 1992). 
The gastritis is usually more marked in the antral and pre-pyloric region of 
the stomach. It cannot be detected reliably by endoscopic appearances but 
is readily apparent on histological examination of mucosal biopsies. 
Epithelial erosions may be present and polymorphs may be visualised 
within the epithelium. However, the most pronounced feature is a marked 
infiltrate of the inflammatory cells within the lamina propria consisting of 
polymorphonuclear cells, plasma cells and lymphocytes (Figure 1). In the 
presence of H. pylori, lymphoid follicles also develop in the mucosa 
(Strickland and Fenoglio-Preiser 1991).
For some time, it remained unclear whether the gastritis was caused by
H. pylori or whether the organism colonised an already inflamed mucosa. 
However, two pieces of evidence provide strong support for the gastritis
8%
Figure 1
G astric antral m ucosal biopsy positive for H elicobacter pylori using 
Warthin-Starry stain, demonstrating chronic gastritis.
being due to H. pylori infection. The first is that eradicating the infection 
results in complete resolution of the gastritis (Rauws et al 1988). The 
second is that self-ingestion studies have shown that infection with the 
organism induces the characteristic changes in a previously normal 
mucosa (Morris and Nicholson 1987). The mechanism by which H. pylori 
induces the inflammatory response in the underlying mucosa is unclear. It 
has been suggested that it may be due to local damaging effects of 
ammonia produced by the organism’s urease activity (Murakami et al 
1988). However, an immune reaction to soluble bacterial proteins seem 
more likely.
1.2 HUMAN IMMUNE RESPONSE TO H. PYLORI
The great majority of patients colonised with H. pylori produce a 
m easurable system ic antibody response to the organism . The 
immunoglobulin classes and sub-classes of these circulating anti-H. pylori 
antibodies are consistent with a prolonged chronic mucosal infection, with 
IgG and IgA predominating and IgM antibodies rarely seen (Kist 1991, 
Rathbone et al 1986, Rathbone 1986, Steer et al 1987). In the single, 
well-documented volunteer study, in which ingestion of H. pylori 
eventually led to chronic gastritis, IgG seroconversion occurred between 
22 and 33 days post-infection (Kaldor et al 1985, Morris and Nicholson
1987). Subsequent studies showed that there was also an initial, 
short-lived, IgM response and a seroconversion of specific IgA (Morris 
and Nicholson 1989). Following eradication of H. pylori infection, there 
is a gradual fall in the circulating antibody levels (Vaira et al 1988, Newell 
et al 1990). In addition to the circulating antibodies (Perez-Perez et al
1988), there is also local production of IgA and IgG classes by 
immunoglobulin secreting B cells which make up a large proportion of the 
lymphoid cell infiltrate in the gastric mucosa (Kirchner et al 1990).
In addition to activation of the B cell limb of the immune response,
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there is also infiltration of CD4- and CD8-positive T cells in H. pylori 
antral gastritis (Engstrand et al 1989, Wyatt and Rathbone 1988, Rathbone 
et al 1989). However, activated T cell clones, specific for H. pylori 
derived antigenic determinants, have still to be isolated from gastric 
mucosa and one cannot exclude these T cells being activated against other 
ingested antigens which are enabled to leak into the mucosa as a result of 
the H. p y lo r i-induced gastritis. These cells are thought to be 
predominantly of the CD4 positive T cells (’helper’ cells) have been 
classified into two main classes: TH1 and TH2 based on differential 
cytokine responses (Karttunen et al 1995). There is some evidence that 
the T cell immune response may be important in the eradication of the 
infection of Helicobacter pylori. Helicobacter pylori infection in mice can 
be eradicated by immunisation with white cell bacterial sonicated and 
these will lead to an active T cell response (Chen et al 1993).
1.5 H PYLORI AND OTHER UPPER GASTROINTESTINAL 
DISEASES IN MAN
1.5.1 DUODENAL ULCERATION
Duodenal ulceration is a common disease in the Western world with 
approximately 1 in 10 of the population being affected by it at some time 
in their life. Though rarely fatal, it causes a great burden on the Health 
Service resources due to the cost of investigations and therapy as well as 
time lost off work. In spite of the prevalence of the disorder, there has 
been little advance in the understanding of its pathogenesis apart from the 
observation that the parietal cell mass in patients with duodenal ulceration 
is approximately twice that of non-ulcer controls (Lam 1984). Most 
research into duodenal ulcer disease over the past 20 years has been 
concerned with the application of acid-controlling drugs which suppress 
acid hypersecretion but do not control the underlying disorder causing it. 
The possibility that duodenal ulcer disease might be associated with an
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infection of the upper gastrointestinal mucosa, and that eradication of this 
infection might cure the disease, has revolutionised our thinking of this 
common disease.
The first piece of evidence linking H. pylori infection with duodenal 
ulcer disease is the high prevalence of the organism in patients with 
duodenal ulceration. The prevalence of H. pylori in subjects with 
duodenal ulceration is greater than 95% compared with a prevalence of 
less than 50% in a control population matched for age, sex and race 
(Marshall et al 1985, Borody et al 1991). Detailed studies have examined 
the very small proportion of patients with chronic duodenal ulceration 
unassociated with H. pylori infection. Approximately half of such patients 
can be explained by false negative results due to the poor sensitivity of 
single tests for detecting the presence of H. pylori (Borody et al 1991, 
Nensey et al 1991). Of the remaining patients who are truly negative for
H. pylori infection but have chronic duodenal ulcer disease, approximately 
50% are taking non-steroidal anti-inflammatory drugs. The very small 
number of remaining patients are an unusual sub-type of duodenal ulcer 
disease and include patients with Crohn’s disease of the duodenum, 
Zollinger-Ellison syndrome, motility disorders and tumours (McColl et al 
1993).
The second piece of evidence incriminating H. pylori infection in the 
pathogenesis of chronic duodenal ulceration is the fact that eradicating the 
infection markedly reduces the ulcer relapse rate. The relapse rate 
following a standard healing course of therapy which does not eradicate 
the infection is approximately 80% at one year, whereas eradication of the 
infection reduces the relapse rate to less than 20% (Marshall et al 1988, 
Coghlan et al 1987). Initially, it was unclear whether the reduced relapse 
rate might be due to an independent effect of the bismuth preparation used 
as part of the eradication drug regimen but patients who received this drug
12
but in whom the infection was not eradicated had a higher relapse rate than 
in those in whom it was eradicated (Coghlan et al 1987). In addition, 
recent studies have shown that one can reduce the duodenal ulcer relapse 
rate by eradicating the infection without any bismuth preparation (Rune et 
al 1992).
The mechanism by which H. pylori infection predisposes to duodenal 
ulceration has remained unclear. There are two main hypotheses. The 
first could be called the histological hypothesis (Wyatt et al 1987). It 
proposes that duodenal ulceration is due to local damage produced by the 
organism lying on islets of gastric metaplasia in the duodenum (Rune
1987). One problem about this hypothesis is that the infection with H. 
pylori is most marked in the pre-pyloric region and if  local mucosal 
damage was the important mechanism, then one would expect a close 
correlation between H. pylori infection and pre-pyloric ulceration which 
has not been confirmed (Thomas et al, 1992).
The other main hypothesis could be referred to as the functional one 
(Thomas et al 1992). This suggests that the infection of the antrum 
somehow disturbs upper gastrointestinal physiology in such a way as to 
predispose to duodenal ulceration. The antrum is important in regulating 
both gastric acid secretion and gastric emptying and alterations in the 
control of either or both of these could predispose to excessive exposure of 
the duodenum to acid and thus lead to its ulceration. The G-cells in the 
antral mucosa are the major source of the hormone gastrin which is the 
major hormone regulating the gastric phase of acid secretion (Roy ton 
1978). The release of gastrin is inhibited by intragastric acid. It is 
therefore possible that the ammonia produced by H. pylori urease activity, 
could block the feedback mechanism and thus result in increased gastrin 
release and consequently excessive acid secretion.
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1.5.2 GASTRIC ULCERATION
The pathogenesis of gastric ulcer is multifactorial with physiological 
and environmental factors contributing (McIntosh et al 1985). Reduced 
mucosal defence appears to be the major abnormality involved in gastric 
ulcer formation and in some individuals gastric acid secretion may be 
lower than controls (Grossman et al 1963, Lanzon-Miller et al 1987, 
Deroda et al 1990). Chronic gastritis is of considerable importance in the 
pathogenesis of chronic gastric ulcer. Helicobacter pylori infection 
associated with gastric ulcer is less obvious than the association it has with 
duodenal ulcer. Between 50-80% cases of chronic gastritis are associated 
with H. pylori infection, and there is increasing evidence that this is a 
casual relationship (Marshall 1985, Rauws et al 1988). Helicobacter 
pylori infection leads to changes in the mucus lipoprotein which leads to 
the damage of the mucosal barrier and thus leads to gastric ulcer 
(Sidebotham 1990). The presence of free radicals due to the inflammatory 
process induced by Helicobacter pylori infection could be another factor.
Non-steroidal anti-inflammatory drugs are one of the important causes 
in the pathogenesis of gastric ulcer. Aspirin has similarly been linked to 
the development of gastric ulceration (Langman et al 1991). Many animal 
and volunteer studies have examined the pathogenesis of mucosal injury 
following both acute and chronic administration of non-steroidal 
anti-inflammatory drugs including aspirin. The damage induced by those 
drags is a complex process and mutli-factorial including interference with 
mucus production, blood flow and bicarbonate production (Yeoman et al
1992).
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1.5.3 H. PYLORI INFECTION AND GASTRIC CANCER
There is now considerable epidemiological evidence showing an 
association between Helicobacter pylori infection and the subsequent 
development of gastric carcinoma. Three separate case-control studies 
have indicated that H. pylori infection increases the risk of subsequently 
developing gastric carcinoma (Nomura et al 1991, Parsonnet et al 1991, 
Forman et al 1991). If this association is causal, then approximately 60% 
of gastric cancers worldwide may be explained by the infection (Correa 
1991).
It is unclear why H. pylori in some patients results in duodenal 
ulceration which is associated with gastric acid hypersecretion, whereas in 
other patients results in gastric cancer which is a disorder associated v/ith 
reduced acid secretion.
1.5.4 H. PYLORI INFECTION AND NON-ULCER DYSPEPSIA
There is considerable interest in a possible role of H. pylori infection in 
non-ulcer dyspepsia (Shallcross et al 1992). Several studies have shown 
that H. pylori infection is more common in patients with non-ulcer 
dyspepsia than in asymptomatic controls. However, it also has to be 
recognised that the majority of subjects with H. pylori infection are 
asymptomatic (Laffeld et al 1989). Studies of the value of eradicating H. 
pylori infection in patients with non-ulcer dyspepsia have produced 
conflicting results. It seems likely that H. pylori infection may play a role 
in a subgroup of patients with non-ulcer dyspepsia and much further work 
will be required to identify this group which may benefit from eradication 
of the infection.
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1.6 DIAGNOSIS OF H PYLORI INFECTION IN MAN
As already mentioned, H. pylori infection can be diagnosed by 
microscopic examination of antral biopsies. In addition, it can be detected 
by culturing antral biopsies. Serology is also of some value but has a low 
sensitivity and specificity (Newell et al 1988, Newell et al 1989). H. 
pylori urease activity provides a valuable way of diagnosing the infection 
and this is used in the breath test and urease slide test which will be 
discussed more fully in the following chapter.
1.7 ERADICATION OF H. PYLORI INFECTION
Eradication as opposed to clearance of H. pylori infection is generally 
defined as being the inability to detect any infection at four weeks 
following completion of eradication therapy. At an early time point after 
completing eradication therapy, the infection may merely be suppressed 
and reappear as the effects of the therapy wear-off.
Eradication of H. pylori infection is difficult. Studies with single 
drugs or even dual therapy have proven relatively ineffective and at 
present the most reliable and effective means of eradicating the infection 
involves 2-3 weeks treatment with three anti-bacterial agents. The agents 
used in this triple therapy include tripotassium dicitratobismuthate, 
metronidazole and either amoxycillin, tetracycline or erythromycin 
(O’Riordan et al 1990). This triple therapy produces eradication rates of 
greater than 90% (Logan 1991). One of the main determinants of the 
success of the triple therapy is the sensitivity of the organism to 
metronidazole; patients with metronidazole-resistant organisms having a 
much reduced chance of eradication (Glupczynski et al 1990, Weil et al 
1990, Becx et al 1990). In this country, resistance to metronidazole is 
present in less than 10% of the population but is more common in other 
European countries and in Africa the majority of strains of H. pylori are
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metronidazole-resistant, possibly due to the frequent use of metronidazole 
or tinidazole for other infections (Glupczynski et al 1990). In addition to 
the problem of bacterial resistance, the current eradication regimen 
produces side-effects in a considerable proportion of subjects (Axon 
1989). Nausea is experienced by most patients and diarrhoea may also 
occur. The patients also have to avoid alcohol during treatment because of 
the possible antabuse reaction with metronidazole. Due to these problems, 
patients undergoing eradication therapy for H. pylori infection must be 
highly motivated. Fortunately, re-infection following successful 
eradication is low (Borody et al 1992, Borody et al 1989).
At present, considerable work is being directed at discovering a more 
effective and more acceptable means of eradicating H. pylori infection. 
P articu lar attention is being paid to the possib ility  of using the 
combination of omeprazole with a single antibiotic. Omeprazole is a 
powerful inhibitor of gastric acid secretion and its elevation of intragastric 
pH may make the local environment less hospitable to H. pylori (Biasco et 
al 1989). In addition, its elevation of intragastric pH may help the 
antibiotic to reach the organism in higher concentrations. Omeprazole has 
also been shown to have some in vitro antibacterial properties (Bugnoli et 
al 1993, Sauerbaum et al 1990).
The present regimen for treating Helicobacter pylori consists of giving 
omeprazole 20mg twice per day plus amoxycillin 500mg t.i.d. and 
metronidazole 400mg t.i.d. for two weeks and the success rate is nearly 
80% on this regime and the other regimen we can use is clarithromycin 
500mg t-i.d. plus omeprazole 20mg twice per day plus amoxycillin 500mg 
t.i.d. for one week. This gives us an almost similar percentage of 
eradication and is effective as the triple therapy (Heatley 1992 and Logan 
et al 1994).
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CHAPTER TWO 
HELICOBACTER PYLORI AND ITS UREASE ACTIVITY
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2.1 INTRODUCTION
H. pylori is remarkable on account of its high urease activity which is 
greater than that of any other urease-producing bacterial species (Molbey 
et al 1988). By means of its urease enzyme H. pylori splits urea into 
ammonia and carbon dioxide, with two molecules of ammonia being 
produced for each molecule of urea split. In vivo, the ammonia produced 
by H. pylori diffuses into the acidic gastric juice where it is trapped as the 
ammonium ion. The carbon dioxide, on the other hand, is absorbed into 
the blood stream and rapidly excreted in the breath. There is evidence that 
the high urease activity of H. pylori helps the organism to survive in the 
unusual intragastric environment and that it may also be involved in 
causing some of the pathological sequelae associated with the infection 
(Levi et al 1989, Chittajallu et al 1991).
2.2 LOCALISATION OF H. PYLORI UREASE ACTIVITY
The ultrastructural localisation of the bacterium’s urease activity has 
been examined by several groups. In electron microscopic studies by 
McLean et al 1985 and Bode et al 1989, strains of H. pylori were 
incubated with sodium tetraphenylboron, an ammonia-precipitating agent 
in the presence of urea. In eleven of the twelve strains studied, there was 
urease activity in the periplasmic region and at the outer membrane, and in 
six of those strains there was also activity in the cytoplasm. The 
localisation of H. pylori urease activity has also been studied by Hawtin 
using monoclonal antibodies and an indirect immunogold technique. In 
these studies using both prefixed bacteria and ultrathin cryosectioned 
bacteria the enzyme was located on the cell surface and in material 
apparently shed from the organism (Hawtin et al 1990).
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2.3 STRUCTURE OF H. PYLORI UREASE
The urease of H. pylori has been partly purified using fast protein 
liquid chromatography by Hawtin et al (1990). The material contained 
lOnm doughnut-like structures when examined by electron microscopy 
and comprised three major polypeptides (61KDa, 56KDa and 28KDa). 
The above material was examined further using polyarylamide gel 
electrophoresis and this showed absence of the 56KDa polypeptide. It 
therefore appears that the urease consists of only two major subunits. The 
28KDa polypeptide appears to be the more important for urease activity as 
only monoclonal antibodies directed against it inhibited or captured urease 
activity.
The genes encoding the two structural subunits of H. pylori urease 
enzyme have now been cloned and sequenced (Clayton et al 1990). The 
derived amino acid sequences of the two H. pylori urease genes indicates 
12/19 amino acids (61%) in common with K aerogenes urease and 15/21 
amino acids (71%) in common with the P. mirabilis enzyme. H. pylori 
urease also shows close homology with jack bean and soybean ureases, 
with almost 57% residues being identical in the bacterial and plant 
. enzymes.
2.4 SIGNIFICANCE OF UREASE ACTIVITY TO THE 
BACTERIUM
H. pylori expends a tremendous amount of its metabolic resources 
producing urease and the enzyme presumably confers significant 
advantages to the bacterium. The production of ammonia, a strong alkali, 
by H. pylori urease has been shown to facilitate the survival of the 
organism in acidic environments. Studies by Marshall etal (1990) showed 
that the organism could survive at pH < 2.5 in the presence of 2mmol/l 
urea but rapidly died at this pH in the absence of urea. The concentration
of urea in gastric juice is approximately 2mmol/l and it is likely that this 
allows the organism to survive in the acidic gastric juice when it is initially 
ingested and before it becomes established in the less acidic environment 
beneath the mucus layer.
H. pylori urease activity may also provide a means by which the 
organism can utilise urea as a nitrogen source. Urease is commonly found 
in spiral organisms in the distal small intestine of rodents where it is 
thought to be important for providing a source of nitrogen for the 
organism (Ferrero et al, 1988). Studies by Greig et al (1991) have shown 
that only a proportion of the ammonia produced the hydrolysis of urea by 
H. pylori is recovered in the incubating medium, and this is consistent 
with the ammonia being incorporated intracellularly. H. pylori possesses 
glutamate dehydrogenase activity which would allow incorporation of 
ammonia into amino acids follow ing com bination with alpha 
ketoglutarate.
ROLE OF UREASE ACTIVITY IN PATHOLOGICAL 
SEQUELAE OF H. PYLORI INFECTION
In addition to assisting the organism’s survival, it is possible that H. 
pylori urease activity and ammonia production may be responsible for 
some of the pathological sequelae associated with the infection. As 
discussed in the preceding chapter, elevation of antral surface pH by the 
ammonia might be responsible for H. pylori related hypergastrinaemia and 
thereby duodenal ulceration. In addition, it has been suggested that the 
ammonia might result in local toxic damage to the gastric epithelial cells 
and be one means by which the organism produces gastritis (Murakami et 
al 1988). H. pylori urease may be involved in producing the gastritis 
independent of any direct toxic effects of the ammonia it produces. A 
significant proportion of the antibodies produced against the organism are 
directed against the protein of the urease enzyme (Hu et al 1990, Hawtin et
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al 1990). The inflammatory infiltrate which characterises H. pylori 
gastritis can be considered to be at least partly due to sensitisation of the 
host’s immune system to H. pylori urease protein (Wyatt et al 1989).
2.6 VALUE OF H. PYLORI UREASE ACTIVITY
IN CLINICAL DIAGNOSIS OF THE INFECTION
The high urease activity of H. pylori provides a useful means of detecting 
the infection in man. Two diagnostic tests based upon the organism’s 
urease activity are commonly employed in clinical practice.
2.6.1 THE UREASE SLIDE TEST
The basic test involves placing an antral gastric biopsy obtained at 
endoscopy in a small well containing urea broth or agar and phenol red. If 
urease activity is present in the biopsy specimen it will hydrolyse the urea 
and the ammonia produced will cause a rise in pH. This rise in pH is 
detected by the phenol red which changes colour from yellow/brown at pH 
6.8 to pink at pH 8.4. A buffer is used to stabilise the test and the 
incubation is performed at 37°C to accelerate the reaction.
A commercially produced urease slide test has been produced by 
Marshall et al (1987). It is called the campylobacter-\ike organism test 
(CLO test) and manufactured by Delta-West Ltd., Perth, Western 
Australia (Fig. 2). After placing the biopsy in the well, adhesive is then 
used to cover the well and the slide is conveniently placed in the 
endoscopist’s trouser pocket to allow it to incubate at near 37°C. The 
CLO test is reported to be almost 100% specific and to have a sensitivity 
of 70% after 1 hour’s incubation and of 90% after 24 hours (McNulty et al 
1989, Dye et al 1988, Schnell et al 1988).
2.6.2 THE UREA BREATH TESTS
The urea breath tests provide a non-invasive means of diagnosing H. 
pylori infection. The tests involve the oral administration of urea which
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Figure 2 : The CLO test rapid urease test for diagnosis of H. pylori
in gastric biopsy specimens. Positive biopsies produce a red colour, 
usually within 1 hour. If the gel remains yellow 24hrs after insertion 
of the biopsy, then H. pylori is not present (sensitivity 95%)-
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has its carbon atom labelled isotopically. In the presence of H. pylori, the 
urea is hydrolysed in the stomach to ammonia and carbon dioxide and the 
latter absorbed and excreted in the breath where it can be detected on 
account of its isotopic label. Either 14C- or 13C-labelled urea may be 
employed. The urea breath tests have a specificity of and sensitivity of 
greater than 90% diagnosing H. pylori infection (Dill et al 1990, Logan et 
al 1991, Veldhuyzen et al 1990, Rauws et al 1989).
The l4C-Urea Breath Test
In our own Radioisotope Department in the Western Infirmary, 
Glasgow, we use the 14C-urea breath test as described below (Fig. 3).
Our patients are fasted overnight from 9p.m. the previous night. On 
arrival they are weighed with indoor clothes and shoes on. The patients 
then clean their teeth without swallowing any water, and discarding any 
rinsings into running water in the basin. This is performed to remove any 
urease producing bacteria present in the mouth. A basal sample of breath 
is then collected. Following this they drink 200ml of Ensure Plus (Abbott 
Laboratories Ltd., Queensborough, Kent), followed by 0.4MBq 
14C-labelled urea in 25ml of water in a disposable paper cup. The cup is 
flushed out twice with 25ml water which the patient also drinks. The 
Ensure Plus is a high lipid drink and is taken to delay gastric emptying 
and retain the 14C-urea in the stomach. After drinking the isotope the 
patient again cleans his teeth to remove any labelled urea from the mouth 
which might be hydrolysed by urease positive bacteria in the mouth. 
Breath samples are then collected at 10, 20, 30,40,50, 60,70, 80,90,100, 
110 and 120 minutes after ingestion of 14C-urea.
The breath samples are collected by blowing into a glass tube 
connected to a scintillator vial containing 2ml indicator solution which is 
60mgm of thymolphthalein dissolved in 500ml of ethyl alcohol and 500ml 
of 1 molar hyamine hydroxide added. The glass tube contains anhydrous
24
I
(UREA) 
NH
ADD 10ml of EMULSIFIER 
SAFE SCINTILLATION FLUID
CALCIUM CHLORIDE 
GRANULES
H-CO, I ml molav HYAMINE 
HYDROXIDE In 
1ml METHANOL 
♦ 1ml ETHANOL
COUNT
UREASE ENZYME 
If H. pylori organisms 
are present
Figure 3
The principle of urea breath test is shown in this figure. If H. pylori urease is 
present in the gastric mucosa, isotope-labelled urea is hydrolysed forming 
C 02 which is expired in the breath. Patients blow through to a liquid trap 
containing methanol, ethanol, hyamine and a pH indicator. The blue 
(alkaline) solution changes to colourless upon C 02 saturation, scintillation 
fluid is added, then counted.
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calcium chloride to dry the breath. The patient blows into the tube until 
the blue colour disappears completely i.e. the hyamine hydroxide is 
neutralised.
Two ml aliquots of the indicator solution are then counted on a liquid 
scintillation counter which has a 14C quench correction curve.
The excretion of 14C-C02 in the breath is then calculated as follows:-
Sample nett D.P.M. (disintegration per minute) x patient weight in kilogram x 100 x 100, 
divided by the given dose D.P.M. The result is expressed as kilogram % dose per mmol 
C 02xl00 .
The results are plotted on a graph of time (min) versus Kgm % 
dose/mmol C 02 x 100.
The 14C-urea in the 14C-urea breath test is either hydrolysed and 
expired as 14C 02, or excreted unchanged as urea in the urine. The total 
dose which will accumulate as the radiation dose is very small and its 
effective half-life is a few hours to a few days. The 14C-urea breath test 
could also be performed in a shorter period i.e. breath samples collected at 
0 and 20 minutes after ingestion of 14C-urea (Bell and Weil 1992).
Restrictions on the use of the 14C-urea breath test are as follows
The 14C-urea breath test should follow the general radiologic procedures and guidelines, 
it should not be given to pregnant women and the 10 day rule is observed.
I3-C-Urea Breath Test
The 13C-urea breath test is similar to the 14C-urea test except that the 
non-radioactive isotope is used and this means that the test can be applied 
without restrictions. Two disadvantages of the 13C-urea breath test are the 
higher cost of the non-radioactive isotope and of measuring it by mass 
spectrometry. The results obtained by the 13C- and 14C-urea breath tests 
are equivalent (Graham et al 1988).
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CHAPTER THREE 
PHYSIOLOGY AND PATHOLOGY OF GASTRIN
2 7
3.1 INTRODUCTION
Gastrin was discovered in 1905 as a gastric acid stimulatory factor in 
the extraction of antral mucosa (Edkins 1905). It was subsequently 
purified as sulphated and non-sulphated Gastrin 17 hecadecapeptide 
(Gregory and Tracy 1964, Yalow and Berson 1970). Understanding of the 
physiology and pathology of gastrin increased after 1969 when it became 
possible to measure the hormone in serum by radioimmunoassay 
(McGuigan and Trudeau 1968, Yalow and Berson 1970).
3.2 GASTRIN BIOSYNTHESIS AND PROCESSING
The complex biosynthetic pathway of gastrin has recently been 
elucidated (Rehfeld and Hilsted 1992). The hormone is initially 
synthesised as preprogastrin which is 101 amino acids in length. This 
peptide is enzymatically cleaved to yield progastrin after which it is 
subjected to a sequence of further protolytic cleavages. The resulting 
carboxyl terminal glycine-extended intermediate is then carboxyamidated 
to produce the biologically active hormone (Rehfeld and Hilsted 1992, 
Walsh 1993). During the cleavage of the larger precursors into smaller 
fragments, various modifications can occur to individual amino acids 
including sulphation making the peptide more resistant to degradation and 
amidation which requires copper, oxygen, ascorbic acid and a pH around 5 
(Eipper et al 1987, Hilsted 1991). The crucial step for biological activity 
is alpha-amidation and the common C-terminal tetrapeptide amide 
(-Trp-Met-Asp-Phe-NH2) has traditionally been regarded as responsible 
for all of the biological effects of gastrin. In 1994, however, several 
groups presented prelim inary evidence that progastrin-derived 
glycine-extended intermediates may possess both trophic (Seva et al 1994, 
Negr6 et al 1994) and acid regulatory properties (Kaise et al 1995).
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After translation of gastrin mRNA (messenger ribonucleic acid) in the 
rough endoplasmic reticulum (RER) and co-translational removal of the 
N-terminal pre or signal peptide from pre-progastrin, the intact progastrin 
is transported to the Golgi apparatus. From the trans-Golgi apparatus, 
small vesicles carry the processing intermediates of progastrin towards the 
basal part of the G-cells (gastrin-producing cells), where gastrin peptides 
are stored (Hakanson et al 1982). As a result of the elaborate biosynthetic 
pathway, the normal antral G-cells in humans release a heterogeneous 
mixture of progastrin products from the mature secretory granules (Hilsted 
and Hansen 1988).
The three molecular forms of gastrin which have biological activity 
with respect to stimulating gastric acid secretion are: big gastrin (G34,) 
little gastrin (G17) and mini-gastrin (G14) (Gregory 1974). The 
Gastrin-17 (G17) is formed mainly in antral mucosa, accounting for 90% 
of the extractable gastrin. However, in the duodenum the majority of 
extractable gastrin is G34 (Berson and Yalow 1971). G17 and G34 
half-lives in the circulation have been found to be approximately five and 
forty-two minutes respectively (Walsh et al 1976). The half-life of G14 is 
similar to that of G17 (Debas et al 1974).
3.3 HOMOLOGY OF HUMAN GASTRIN WITH OTHER 
PEPTIDES
Most biologically active peptides occur in peptide families whose, 
members display a significant structural homology. The occurrence of 
peptide families reflects development by gene duplication and subsequent 
mutation from a single ancestral peptide gene for each family (Larsson et 
al 1977). Gastrin is a member of the peptide family which includes 
cholecystokinin (CCK). Both are isolated from the gastrointestinal tract
and shown to be present in the brain. Different forms of these peptides are 
released into the circulation by differential proteolysis. Gastrin and CCK 
share the same carboxyl terminal pentapeptide sequence. The carboxyl 
(COOH) terminus tetrapeptide represents the region responsible for 
biological activity of both hormones whereas the rest of the two molecules 
only modifies their selectivity and potency for different target cells. The 
main difference between gastrin and CCK is in the tyrosine residue which 
is present six amino-acids from the COOH terminus in gastrin, whereas 
CCK has a tyrosine on the seventh amino-acid. The tyrosine residues may 
be sulphated in various peptides of CCK but are only partially sulphated in 
gastrin. The presence of a sulphate residue increases the affinity of gastrin 
for its receptor and sulphated G17 was a nineteen fold higher affinity for 
gastrin/CCKB receptors compared to non-sulphated G17 (Huang et al 
1989). The peptides of gastrin/CCK family exert their effects by 
interaction with at least three different types or states of receptor (Hays et 
al 1980, Saito et al 1980, Soil et al 1984). These include pancreatic type 
(CCKa), the cerebral colorectal type (CCKfi), and the gastrin receptors. 
The CCK and gastrin exert their effect on the same receptors, although the 
latter two types are now thought to be the same. Cholecystokinin exerts 
trophic effects via gastrin/CCKB receptors with similar affinities (Hughes 
et al 1993).
THE G AND D CELLS WITHIN GASTRIC MUCOSA
In the normal mammalian organism, most gastrin is produced by the 
antral G cell (Larsson et al 1980) which are part of APUD cells, found 
throughout the gastrointestinal mucosa. Other cells in the same system 
include D-cells which secrete somatostatin. Gastrin and somatostatin are 
two potent regulatory peptides; both influence the secretion of gastric acid 
which is stimulated by gastrin and inhibited by somatostatin depending on
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the pH value in the stomach and duodenum (Barros et al 1975, Polak et al 
1978). G- and D-cells are concentrated in the antrum (Canese and 
Bussolati 1977). G-cells are often found in close contact with finger-like 
cytoplasmic processes of somatostatin cells (Larsson et al 1979) and with 
nerve fibres containing bombesin-like peptides (Holst et al 1987) such as 
gastrin releasing peptide (GRP), (Guo 1987, Holst et al 1987). The G-cell 
ultrastructure is characterised by cytoplasmic granules which are 
accumulated in the basal and paranuclear cytoplasm. The granules 
represent the main storage sites for hormonal peptides. The D-cells have 
long finger-like cytoplasmic processes that directly contact neighbouring 
cells i.e. parietal cells and G-cells. The morphological evidence for a 
paracrine mode of action to gastric D-cells is the presence of somatostatin 
receptors on their adjacent cells (Larsson 1979).
3.5 THE REGULATION OF GASTRIN RELEASE
Gastrin release is a complex process. Ingestion of a meal, especially 
one containing beef protein, is the most important stimulant of gastric 
release. Peptone and amino acids derived from partial digestion of protein 
are particularly  potent (M cArthur et al 1988), whereas fat and 
carbohydrates are ineffective. Similarly, gastrin is released when 
intragastric pH rises above three and conversely, antral acidification after a 
meal potently inhibits gastrin release (Schubert 1993).
Vagal innervation stimulates gastrin release, probably via release of 
gastrin-releasing peptide (GRP) from enteric nerve endings. Vagal 
reflexes can also inhibit gastrin release, although the mechanism of this is 
unclear (Walsh 1994). A number of gastrointestinal peptides also inhibit 
gastrin release, but som atostatin is by far the most im portant. 
Somatostatin cells are located in close proximity to gastrin cells of the
antrum and parietal cells of the fundus. Somatostatin exerts a continuous 
inhibitory paracrine effect on the secretion of gastrin and acid (Chiba and 
Kinoshita 1993). Other inhibitors of gastrin release include secretin, 
glucagon, vasoactive intestinal polypeptide (VIP), cholecystokinin, gastrin 
inhibitory peptide (GIP) (Rayford et al 1974) and calcitonin (Becker et al 
1974, Gregory 1974). Others include prostaglandin E analogues in 
parietal cells which interact with inhibitory receptors coupled to adenylate 
cyclase (Chen et al 1988, Ippoliti et al 1976). All these inhibitors may be 
acting indirectly via stimulation of somatostatin release and their full 
physiological importance is still unclear.
EFFECTS OF GASTRIN ON GASTRIC ACID 
SECRETION
The major physiological role of gastrin is stimulation of gastric acid 
secretion. An ATP-dependent ion pump, situated in the secretory 
membrane of the stimulated parietal cell is directly responsible for acid 
secretion. Gastrin binding to the parietal cells using [125I-Tyr] gastrin has 
been dem onstrated by autoradiography (Nakamura et al 1987). 
Kuamamoto and colleagues demonstrated specific 125I-G17 binding to 
gastric fundic mucosa from a duodenal ulcer patient (Kuamamoto et al 
1989).
The activity of the parietal cell is controlled by receptors for 
acetylcholine, histamine and gastrin on the basolateral cell membrane 
(Nakamora et al 1987). Other receptors include Ax adenosine, epidermal 
growth factor, enteroglucagon and adenergic compounds (Gerber et al 
1985). Stimulation of these receptors modulate the level of protein kinase 
in the cell and brings about the change from resting to stimulating 
structure. In recent years, an increasing number of receptor antagonists 
for gastrointestinal peptides have become available as powerful tools with 
which to study many aspects of gastrointestinal function. At least eight
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antagonists for gastrin CCK/fi have been developed (Presti and Gardner 1993).
3.7 TROPHIC EFFECTS OF GASTRIN
The physiological trophic effect of gastrin on the gastrointestinal 
mucosa was first observed clinically in patients with Zollinger-Ellison 
syndrome. This disease results in a gastrin secretory endocrine tumour of 
the digestive tract and patients are noted to have thickened gastric rugae, 
gastric mucosal hyperplasia and an increased parietal cell mass (Ellison et 
al 1967). Patients with low circulating gastrin concentration due to 
antrectomy, demonstrate mucosal atrophy (Lees et al 1968).
In 1969, Crean and Johnson were the first to report trophic effects of 
gastrin on the gastric mucosa of rats following injection of pentagastrin 
(Crean et al 1969, Johnson et al 1969). Since these studies, evidence for a 
physiological important trophic role for gastrin in the stomach has steadily 
accumulated.
Johnson (1977) found that intraperitoneal injection of pentagastrin 
(250|Xg/kg_1) had no effect on [3H] thymidine incorporation of antral 
mucosa but stimulated oxyntic mucosal thymidine uptake by 150 times 
compared to control rats. Others have confirmed these findings (Balas et 
al 1985) although Lehy et al (1979) found gastrin to be equally effective at 
stimulating [3H] thymidine uptake in both glandular and antral portions of 
the rat stomach. However, the weight of evidence would suggest that 
antrum is not regulated trophically by gastrin. Johnson pointed out that 
this is perhaps not surprising, given the neuroendocrine function of the 
antrum (Johnson 1977).
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3.8 GASTRIN AND ENTEROCHROMAFFIN-LIKE 
(ECL) CELLS
ECL cells constitute the major endocrine cell population in the 
acidopeptic mucosa and are small, irregularly shaped and heavily 
aggrophilic with different methods of staining (Capella et al 1991, Solcia 
et al 1975). ECL cells are poorly represented in the cardia and are absent 
from the pyloric gland area. In the oxyntic gland, ECL cells are scattered 
in the deep and intermediate regions with few observed in the neck and none 
in the surface epithelium (Capella et al 1971). Histamine is the only 
messenger/mediator which has been demonstrated to restore the ECL cells 
of all species (Hakanson et al 1986). These cells produce and store 
histamine along with a yet undefined peptide(s). The first detailed 
description of non-tumour endocrine growth arising in the oxyntic mucosa 
were of patients with pernicious anaemia and chronic atrophic gastritis 
(Rubin 1969). In human pathology, variable patterns of ECL cell 
hyperplasia are observed in conditions of longstanding hypergastrinaemia 
evoked by two different mechanisms, achlorhydria in chronic active 
gastritis and gastrin cell tumour in the Zollinger-Ellison syndrome with or 
without multiple endocrine neoplasia syndrome. The key role of gastrin in 
determining ECL cell growth is shown by the observation that in chronic 
active gastritis patients, the withdrawal of hypergastrinaemia following 
antrectomy induces a dramatic shrinking of proliferated ECL cells, 
eventually leading to complete disappearance of hyperplastic changes 
(Richards et al 1987, Olbe et al 1988, Hirschowitz et al 1992). Sustained 
hypergastrinaemia induces either by continuous infusion of gastrin (Rybert 
et al 1990) or by chronic treatment with inhibition of acid secretion such 
as ranitidine (Havu et al 1990) or omeprazole (Havu 1986, Ekman et al 
1985), results in ECL cell hyperplasia with continued treatment. Larsson 
showed ECL carcinoid tumours developed in the stomach of treated
(Larsson et al 1988). The role of gastrin in stimulating proliferation of 
ECL cells has been reviewed recently (Hakanson and Sundler 1991, Berlin 
1991). The main explanation of the proliferation pressure on the ECL cell 
hyperplasias is not fully understood. Clinical evidence suggests that other 
factors both genetic and environmental are required to induce ECL cell 
transformation and carcinoid tumour (Solcia et al 1993). Further work is 
required to establish the exact relation between hypergastrinaemia and the 
ECL cells.
CAUSES OF HYPERGASTRINAEMIA
Treatment with inhibitors of acid secretion such as ranitidine or 
omeprazole will cause hypergastrinaemia (Havu 1986, Lamberts et al
1993). The role of gastrinoma Zollinger-Ellison syndrome is well 
established and the subject has been reviewed by Isenberg et al (1973) and 
Walsh and Grossman (1975). Other conditions include antral G-cell 
hyperplasia and isolated retained antrum (Berson and Yalow 1972). Basal 
and meal-stimulated gastrin were both observed to be higher in patients 
with pyloric stenosis compared with both normal subjects and non-stenotic 
ulcer patients (Tani and Shimazu 1977), while other workers (Hamburg et 
al 1979) found no difference in the fasting and post-feeding serum gastrin. 
A large proportion of patients with chronic renal failure have increased 
serum gastrin concentration. This appears to be related to the severity of 
the renal failure as affected by the serum creatinine level (Hansky et al 
1975). Serum gastrin levels remain high in patients undergoing chronic 
haem odialysis and were less elevated in patients who had renal 
transplantation (Doherty et al 1978). The increase in serum gastrin levels 
may also be a reflection of atrophic gastritis and gastric hypo-acidity 
(Mitchell et al 1979). A direct correlation was found between G-cell 
density and parathyroid function in patients with chronic renal failure,
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suggesting that secondary hyperparathyroidism may play a role in the 
gastrin elevation (Crivelli et al 1979).
Fasting gastrin also increased after vagotomy in duodenal ulcer patients 
(Walsh and Grossman 1975) and in non-ulcer patients (Lam et al 1978). 
Hypergastrinaemia has been reported in rheumatoid arthritis (Rowden et al 
1978), cirrhosis of the liver (Lam 1976) and in patients with intestinal 
resection (Straus et al 1974).
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AIM OF THE THESIS
The aims of this thesis are to study:
(1) The effect of H. pylori infection on serum gastrin concentrations.
(2) The role of bacterial ammonia production in producing hypergastrinaemia.
(3) The effect of H. pylori status on serum gastrin during proton pump
inhibitor therapy.
(4) The effect of proton pump inhibitor therapy on H. pylori infection.
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CHAPTER FOUR
EFFECT OF H. PYLORI INFECTION ON BASAL 
AND MEAL-STIMULATED PLASMA 
GASTRIN CONCENTRATIONS
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4.1 INTRODUCTION
There is increasing evidence that Helicobacter pylori (H. pylori) 
infection is important in the development and relapse of duodenal 
ulceration (Graham 1989). However, the mechanism by which this 
chronic bacterial infection predisposes to ulceration of the duodenum 
remains unclear. As the infection mainly involves the gastric antrum 
where the gastrin producing G-cells are located, it could interfere with 
gastrin release and thereby affect gastric acid secretion. In order to 
investigate this we have examined basal and meal stimulated plasma 
gastrin concentrations and gastric acid status before and one and seven 
months after eradication of H. pylori infection in duodenal ulcer patients.
4.2 PATIENTS
Ten patients (9 men, 1 woman, median age 49 years; range 29-65) 
confirmed endoscopically to have duodenal ulceration within the previous 
year were studied. Seven were workers. None had evidence of active 
ulceration at endoscopy performed within one month of entry to the study. 
Antral biopsies obtained at this examination showed gastritis associated 
with H. pylori-like organisms and gave a positive reaction to the rapid 
urease test (CLO test) described by Marshall et al (1987). All the patients 
had been treated with H2 antagonists but none had undergone gastric 
surgery.
4.3 METHODS
On entry to the study each patient had a 14C-breath test and a combined 
study of daytime intragastric pH and plasma gastrin. Six patients also had 
studies of night-time acid output. These tests were repeated along with 
repeat antral biopsies 4 weeks after completing a one month course of
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tripotassium dicitrato bismuth (De-Nol tab) 120mg four times a day, 
metronidazole 400mg three times a day and amoxycillin 250mg three 
times a day. Seven months after completing eradication therapy nine 
patients had repeat breath tests and combined studies of daytime 
intragastric pH and plasma gastrin concentrations and six of them also had 
repeat studies of night-time acid output.
4.3.1 COMBINED INTRAGASTRIC pH/GASTRIN STUDIES
The com bined studies of in tragastric pH and plasm a gastrin 
concentrations were performed at least four weeks after withdrawal of any 
acid inhibitory agents. The patients reported fasted at 0830h and a 
combined glass electrode (Radiometer, GK2802C) was passed perorally 
into the body of the stomach where its position was confirm ed 
radiologically. The electrode was connected to a digital recorder 
(Digitrapper MKII, Synectics Medical) which registered the pH every 4 
seconds from 0830h until 2100h. At the start and completion of each 
recording the electrodes were calibrated using standard buffers of pH 1.07 
(Synectics 5002) and 7.01 (Synectics 5001). During the first 30 minutes 
of the pH recording and with the patient still fasted, 10ml venous blood 
samples were taken at 15 minute intervals for gastrin determination. The 
patient then took a standard OXO breakfast (40kcal) consisting of two 
beef cubes (OXO Ltd., Croydon, England), dissolved in 200ml water at 
50°C and further venous blood samples were taken at 10 minute intervals 
for 90 minutes. On each study day patients were given standard meals 
(700kcal each) at 1230h and 1730h. Smokers documented their cigarette 
consumption on their first study day and smoked an identical number on 
subsequent study days.
Seven of the patients studied had participated in a four week H2 
antagonist therapy study 3-6 months earlier. The pre-treatment day of that 
study employed the identical protocol to the present study. It was
to
therefore possible to compare these patients’ basal and OXO-meal 
stimulated gastrin values when they had first been studied in this way with 
the results of their pre-treatment study day for the present study. In this 
way, it was possible to assess whether repeating the test in itself could 
affect the gastrin values.
4.3.2 NIGHT-TIME ACID OUTPUT
In the patients who also had studies of night-time acid output, the pH 
electrode was removed at 2100h and replaced by a size 14F vented gastric 
tube (Andersen Inc., New York). Constant aspiration was performed 
throughout the night (2300h-0800h) and the gastric juice analysed as 
hourly aliquots. The volume and pH of each collection were recorded and 
hydrogen ion concentration measured by titration with 0.1N Na OH to 
pH7 using an autotitrator (Radiometer ETS 822). During the night-time 
acid output studies performed before therapy and one month post 
treatment further venous blood samples for gastrin determination were 
obtained at 2 hourly intervals from 2300h until 0700h.
4.3.3 14C-UREA BREATH TEST
The 14C breath tests were performed within 5 days of the combined 
acid and gastrin studies. After an overnight fast the patients drank 250ml 
Ensure Plus (Abbot Laboratories, England) immediately followed by 
0.4MBq 14C-urea (Amersham International) in 25ml water. Breath 
samples were collected at 10 min intervals for 2 hours and analysed as 
described by Marshall and Surveyor (1988). As the 20 min sample has 
been shown to be the most discriminating (Bell et al 1987), this was 
selected for assessing the effectiveness of the eradication therapy.
4.3.4 HISTOLOGY
Antral biopsies were fixed in formol saline, embedded in paraffin wax, 
sectioned at 4um and stained with Haematoxylin and Eosin. They were all
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examined blind by a single pathologist (SD) and given a gastritis score of 
between 0 and 10. Chronic inflammatory infiltrate in the mucosa was 
scored as 0-2, lamina propria polymorph infiltrate as 0-3, intraepithelial 
polymorph infiltrate as 0-3 and mucosal erosions as 0-2 as described by 
Rauws et al (1988).
4.3.5 GASTRIN DETERMINATION
The venous blood samples were immediately centrifuged at 4°C and 
the plasma stored at -20°C. Gastrin determination was performed by 
radioimmunoassay using antibody R98 which has a sensitivity of 5ngA 
(Ardill 1973). The pre- and one month post-treatment samples were 
assayed in the same batch. When the seven month post treatment samples 
were assayed, stored samples from each patient’s pre- and one month post 
treatment study were re-assayed along with them and their values were 
within 5% of the original in each case.
The basal gastrin value for each patient was determined by taking the 
median of the three samples obtained at 15 min intervals prior to the OXO 
meal. The night-time gastrin value was taken as the median of the 5 
samples obtained at 2h intervals through the night. The integrated gastrin 
response to the OXO meal was taken as the area under the plasma gastrin 
time curve calculated by the trapezoid method.
4.3.6 INTRAGASTRIC pH ANALYSIS
The intragastric pH data were transferred from the Digitrapper recorder 
to an IBM Compatible computer (Amstrad PC 1512 HD20) and analysed 
using the GastrograpH program (Ver 5.0, 1987, Gastrosoft Inc). For each 
patient the median value of all their daytime recordings (0900-2 lOOh) was 
calculated and called their daytime pH. More detailed analysis was 
performed of the intragastric pH response to the OXO meal as this was the 
meal during which plasma gastrin was monitored. This included the
measurement of the peak pH achieved and the time the pH was above 2 in 
the hour following this meal. For the patients in whom H. pylori was 
successfully cleared, integrated median daytime pH profiles prior to and 
following eradication were created, by combining individual median 
values at 10 minute intervals using he Statphac program (Ver 2.07, 1987, 
Gastrosoft Inc).
Statistical comparison of values before and after eradication of H. 
pylori were performed using the two-sided Wilcoxon’s paired samples 
ranking test.
The study was approved by the Hospital Ethical Committee and all 
patients gave written informed consent before entry.
RESULTS
The one month course of triple therapy eradicated H. pylori in 9 of the 
10 patients. This was confirmed by the absence of the organism in repeat 
antral biopsy, a negative CLO test and normalisation of the 14C-urea 
breath test. In these 9 patients the 20 min breath test values (percentage 
14C dose per mmol C02 x 100 x kg body weight) ranged from 72-171 
(median 135) prior to eradication therapy and were 0-5 (median 2), one 
month following therapy (p < 0.01). In each of the 8 of these patients who 
had repeat breath tests seven months after completing therapy, the values 
were again less than 5. In the one patient in whom the bacterium was still 
present in the antral biopsy and whose CLO test remained positive one 
month after therapy, the 20 min breath test value was 60 pre-treatment, 40 
one month post treatment and 59 seven months post treatment.
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4.4.1 HISTOLOGY
In the 9 patients in whom the bacterium was eradicated, the median 
gastritis score prior to treatment was 5 (range 1-8) and fell to 1 (range 0-1) 
one month post treatment (p < 0.01). In the patient in whom the organism 
was not cleared, the score was 5 before therapy and 5 following it.
4.4.2 PLASMA GASTRIN CONCENTRATIONS
In the 9 patients cleared of H. pylori their median basal gastrin 
concentration fell from 30ng/l (range 20-60) to 20 (range 5-35) at one 
month following eradication (p < 0.02) and their integrated gastrin 
response to the OXO meal from 3,650ng/l.min (range 1,875 - 6,025) to 
1,800 (range 1,200 - 3,075) (p < 0.01) (Fig. 4). In each of the 5 patients 
cleared of the organism and studied overnight, there was a fall in their 
night-time gastrin concentration; the median night-time concentration 
being 40ng/l (range 20-55) compared with 25 (range 15-30) one month 
following therapy. In the eight patients studied seven months after 
eradication of the organism their median basal gastrin concentration 
(median 15, range 5-20) and their integrated gastrin response (median 
1,312, range 875 - 2,025) were similar to the respective values at one 
month post treatment. In the single patient in whom H. pylori was not 
eradicated the integrated gastrin response values before, at one month and 
at seven months after therapy were 5,075ng/l.min; 5,450ng/l.min and 
3,800ng/l.min respectively.
In the 7 patients who had undergone an identical pre-treatment study 
day 3-6 months previously, the gastrin values on that occasion were 
similar to their values on the pre-treatment day of the current study. Their 
median basal gastrin concentration from the previous study was 42ng/l 
(range 30-55) compared with 35ng/l (20-60) for the current study, and 
their median integrated gastrin response was 4,075ng/l.min (range 
3,350-5,225) compared with 4,975 (range 1,875 - 6,025).
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4.4.3 INTRAGASTRIC pH
In the 9 patients in whom H. pylori was eradicated there was no 
significant difference between their overall daytime pH values before 
treatment (median 1.4, range 1.1 - 2.1) and one month post treatment (1.4,
1.1 - 2.3) (Fig. 5) or seven months post treatment (1.4, 1-2.1) (Fig. 5). In 
these patients, however, the peak pH reached in response to the buffering 
effect of the peptide meal was higher one month following eradication 
(median 4.2, range 3 - 5.7) than before treatment (3.4,1.5 - 4.5) (p < 0.02). 
In addition, the time the pH was above 2 following this meal was longer 
one month after treatment (median 11 min, range 2-15) than before (30 
seconds, 0 -1 1  min) (p < 0.03). At seven months post-eradication, the 
peak pH reached after the peptide meal (2.9, 1.8-7) and the time pH was 
above 2 (6 min, 0 -1 5  min) were not significantly different from the 
pre-eradication values.
4.4.4 NIGHT-TIME ACID OUTPUT
Night-time acid output (mmol/lOh) was similar before (median 86, 
range 52-114), one month after eradication (76, 50-143) and seven months 
after eradication (94,63-106) (Figure 6).
4.5 DISCUSSION
This study demonstrates that eradication of H. pylori is associated with 
a marked and sustained fall in both basal and meal stimulated plasma 
gastrin concentrations in duodenal ulcer subjects. The observation that the 
gastrin values from an identical pre-treatment study day 3 - 6  months 
previously were similar to those on entry to this study indicates that the 
fall in gastrin was not merely due to exaggerated levels on the first test day 
of this study. A similar fall in fasting gastrin concentration has been noted
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following eradication of the organism in children with a variety of upper 
gastrointestinal disorders (Oderda et al 1989). Levi et al (1989) noted a 
similar fall in meal stimulated gastrin concentrations but not in basal 
concentrations in duodenal ulcer subjects two days after completing H. 
pylori eradication therapy. Healthy volunteers found to have H. pylori 
also have elevated 24h gastrin concentrations (Smith et al 1989). There is 
convincing evidence, therefore, that chronic infection with H. pylori 
results in increased circulating levels of gastrin. In view of the high 
prevalence of the bacterium in healthy subjects, the currently accepted 
normal range for plasma gastrin and its physiological control require to be 
re-assessed in non-infected subjects.
The mechanism by which H. pylori increases gastrin levels is unclear. 
Levi et al (1989) have proposed that it is due to the ammonia produced by 
the organism’s urease enzyme raising the pH in the vicinity of the antral G 
cells. In this way, the organism would interfere with the physiological 
suppression of gastrin release by gastric acid leading to inappropriate 
circulating levels of the hormone. An alternative explanation for the 
hypergastrinaemia is that it is due to the chronic inflammation which the 
bacterium induces in the antral mucosa where the G cells are located.
In spite of the marked lowering of gastrin levels the overall daytime 
intragastric pH and night-time acid output were unaltered following 
eradication of the organism. This does not exclude a reduction in 
meal-stimulated acid secretion as in situ pH monitoring registers only the 
hydrogen ion concentration of the gastric contents and not the volume of 
juice secreted. The major physiological role of circulating gastrin may be 
in regulating meal-stimulated acid secretion. The more marked pH rise in 
response to the buffering effect of the OXO meal one month after 
eradicating H. pylori would be consistent with reduced acid secretion in 
response to this meal. The major difference between the intragastric pH
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profile of duodenal ulcer patients and controls is reduced buffering effect 
of meals in the former (Bumm & Blum 1987).
In addition to directly stimulating parietal cells to secrete acid, gastrin 
also exerts a trophic effect on the oxyntic mucosa (Willems & Lehy 1975) 
and prolonged hypergastrinaemia produces parietal cell hyperplasia (Crean 
et al 1969). Loss of the trophic effect on the parietal cells due to the fall in 
circulating gastrin would be expected to result in a reduction in both basal 
and meal stimulated acid secretion. The half-life of parietal cells is 23 
days in mice (Ragins et al 1968) and presumably longer in man and, 
therefore, removal of a trophic influence might not be apparent for several 
months. However, we were unable to detect any evidence of lowering of 
gastric acid status seven months following eradication and indeed at this 
time there was not even a significant difference in the pH response to the 
buffering effect of the OXO meal.
It is possible that the lack of any convincing change in gastric acid 
status accompanying the highly significant lowering of circulating gastrin 
is due to the insensitivity of intragastric pH monitoring at detecting 
changes in meal-stimulated secretion. However, it is necessary to consider 
other reasons for the lack of change in acid status. One explanation is that 
the gastrin released in the presence of H. pylori infection is of reduced 
biological activity. This could occur as a resu lt of the chronic 
inflammation of the antral mucosa resulting in damage to the G cells and 
leakage of biologically inactive but immunologically recognisable 
fragments of the hormone.
Another clue to the reason for the discrepancy between the change in 
plasma gastrin and gastric acidity could be the observation that acute 
infection with H. pylori results in marked hypochlorhydria which may 
persist for several months (Marshall et al 1985, Graham et al 1988) and 
which may be explained by a direct inhibitory effect of the bacterium on
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the parietal cells (Defize et al 1988). Some inhibition of parietal cell 
function may persist in patients with chronic infection and counteract the 
effect of the increased gastrin. On eradicating the infection there would be 
both lowering of gastrin and removal of the inhibition of parietal cells 
producing no net effect on acid status. It is even possible that the 
increased gastrin level is itself in part a secondary response to inhibition of 
parietal cell function by H. pylori.
This study clearly demonstrates that eradication of H. pylori results in a 
marked fall in gastrin levels in duodenal ulcer subjects. However, the 
inability to detect any convincing change in acid status casts doubt on a 
major role for gastrin in the link between H. pylori infection and duodenal 
ulceration. It is possible that subjects with H. pylori also have 
abnorm alities of antral hormones involved in the regulation of 
gastro-duodenal motility and which could explain their predisposition to 
duodenal ulceration.
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CHAPTERS
EFFECT OF HELICOBACTER PYLORI INFECTION ON 
INTRAGASTRIC UREA AND AMMONIA 
CONCENTRATION - VALUE IN DIAGNOSIS
INTRODUCTION
Helicobacter pylori (H. pylori) infection of the gastric antral mucosa is 
present in the vast majority of duodenal ulcer patients and eradication of 
the infection markedly reduces the ulcer relapse rate (Marshall et al 1988). 
The mechanism by which the infection predisposes to duodenal ulcer is 
likely to be related to its stimulation of increased gastrin release. The 
mechanism by which the infection stimulates gastrin release is unknown 
but may be related to production of ammonia by the bacterium. In this 
chapter we examine the effect of H. pylori on the concentration of urea 
and ammonia in gastric juice.
In addition to furthering our understanding of the mechanism by which 
H. pylori may raise serum gastrin, the measurement of urea and ammonia 
in gastric juice may be of value in the clinical diagnosis of H. pylori 
infection. At present there are two measurement of the rate of ammonia 
formation following incubation of an antral biopsy in a urea containing 
medium (Marshall et al 1987). There are several variations of this method 
and most detect the ammonia formed by means of the change in colour of 
a pH indicator such as phenol red. The time from incubation of the biopsy 
until the change in colour is apparent and varies from 3-24 hours. The 
second method involves the oral administration of 14C or 13C labelled urea 
and subsequent analysis of labelled C 02 excreted in the breath (Bell et al 
1987, Marshall et al 1988, Graham et al 1987). This test takes 1-2 hours 
to perform and the final result is not usually available until the following 
day at the earliest.
In this chapter we assess the effect of H. pylori on gastric juice urea 
and ammonia concentrations and the value of their measurement in 
diagnosing H. pylori status.
PATIENTS AND METHODS
Twenty seven patients (21 men, age range 18-64 years) with a history 
of endoscopically proved duodenal ulceration were examined. Two of 
them were taking ranitidine but none had been prescribed omeprazole. All 
had normal renal function. Twelve were examined on one occasion only, 
having never received any anti-H. pylori treatment. Twelve were 
examined before and one month after completing a four week course of 
tripotassium dicitrato bismuthate (120mg t.i.d.)., metronidazole (400mg 
t.i.d.), and amoxycillin (250mg t.i.d.). Three patients were examined only 
one month after the same treatment. At each time point examined, an 
upper gastrointestinal endoscopy and 14C urea breath test were performed. 
All the patients had fasted for 16 hours before endoscopy.
During the endoscopy and just after entering the stomach, 2ml of 
gastric juice were aspirated through the suction channel of the endoscope 
and collected in a trap inserted in the suction line. Routine inspection of 
the upper gastrointestinal tract was then performed and after this an antral 
biopsy specimen was obtained for histological examination. The 
specimen was fixed in formalin before staining with haematoxylin and 
eosin. The severity of histological gastritis was scored as described by 
Rauws et at and the presence of H. pylori noted.
The gastric juiced samples were stored frozen at -20°C until analysed. 
Before analysis, the samples were centrifuged at 3000g for 10 minutes to 
remove the mucus. The concentration of ammonium was measured in the 
supernatant after dilution in 0.2mol/l phosphate buffer pH 7.4 using an 
enzymatic method (Sigma Chemical Co., Dorset, U.K.) adapted for the 
Cobas Bio (Roche, Welwyn Garden City, U.K.) Studies were performed 
to assess the reliability of this method for determining ammonium 
concentrations in gastric juice. Urea concentrations were measured by a 
urease enzymatic method (SMAC 1, Technicon, Basingstoke, U.K.).
Within five days of each endoscopic examination, a 14C urea breath test 
was performed. After a 14 hour overnight fast, the patients drank 240ml 
of Ensure Plus (Abbott, Maidenhead, U.K.) to delay gastric emptying, 
followed by 0.4MBq 14C urea in 20ml water. Samples of breath C 02 were 
collected every 10 minutes for 30 minutes before administration o the 
isotope and for 120 minutes afterwards. The appearance of 14C labelled 
C 02 in the breath samples was followed by liquid scintillation counting. 
The area under the curve of the breath test was calculated using the 
trapezoide rule for the time period 0-30 minutes, 0-40 minutes, 0-60 
minutes, and 0-120 minutes of the test.
RESULTS
In the 24 duodenal ulcer patients who had not received anti-H. pylori 
treatment, the organism was present in each on examination of their antral 
biopsy specimen. In each of these patients antral gastritis was also present 
and their median score for severity of gastritis was 5 (range 2-8). In 14 of 
the 15 patients examined one month after completing a course of anti-H. 
pylori therapy, no H. pylori like organisms were identified and none had 
gastritis scores greater than 1. In one patient the treatment failed to 
eradicate the infection and the bacterium was still present on the mucosa 
and associated with persisting antral gastritis with a severity score of 5. 
This patient’s pretreatment aspirate ammonium and urea concentrations 
were 2.5mmol/l and 0.7mmol/l respectively, while after treatment they 
were 2.7mmol/l and 0.7mmol/l respectively.
Analysis of the area under the breath test curve two hours after isotope 
administration showed clear separation of the patients with histological 
evidence of the infection and who had never received anti-H. pylori 
treatment (Table 1).
The values in the former were all less than 20 (range 3-18) and in the
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Area Under the Breath Test Curve (Median) (Range) (% Dose/mmool/COjXkgxmin)
UNITS 0-30 0 - 40 0-00 0-120 Peak of 10
min. min. min. min. and 20 min breath test
value % dose/mmol Co2 Kg
Pre eradication 25(6-42) 41(12-69) 76(23-127) 152(63-267) 137(39-225)
of H. pylori 
(n = 24)
Post eradication 0.6 (0.1-1.1) 0.7(0.3-2.5)1.7(0.8-7.2)5.0(3.0-18.0) 2.6 (0-5.1)
of H. pylori 
(n = 14)
TABLE 1: AREA UNDER THE BREATH TEST CURVE BEFORE AND AFTER 
ERADICATION OF H. PYLORI.
latter all greater than 60 (range 63-267). In the one patient with 
histological evidence of failure of eradication the value was 114 before 
treatment and 90 after treatment. She was therefore included only as a 
positive for H. pylori in the further analysis. There was also complete 
separation of the two groups with the calculated area under the curve for 
the first 30 minutes, 40 minutes, and 60 minutes of the breath test. Even 
the higher single value of either of the 10 minute or 20 minute breath test 
results was also found to separate the patients clearly into the two groups, 
indicating that a shortened 20 minute breath test could be as useful as the 
complete two hour test.
The method of ammonium measurement in the gastric juice samples 
was assessed. The intra-assay coefficient of variation at 10mmol/l 
ammonium concentration was 1.0% while the inter-assay coefficient of 
variation was 2.0%. Using samples from patients, the intra-assay 
coefficient of variation, including dilution, varied from 8.5% at an 
ammonium concentration of 2.3mmoll to 1% at an ammonium 
concentration of 13.0mmol/l. The measured ammonium concentration in 
patients’ samples was linear with serial dilution. The detection limit for 
the assay was 30p.mol/l. Samples kept in a freezer at -20°C also showed 
no significant change in ammonium concentration over a 21 day period.
The median (range) gastric juice urea concentration was 0.8mmol/l 
(0.5-2.9mmol/l) in those with the infection compared with 2.1mmol/l 
(l,0-3.7mmol/l) in the patients in whom it had been eradicated (p<0.001) 
(Fig. 7). The median (range) gastric juice ammonium concentration was 
3.4mmol/l (1.0-13.0mmol/l) in infected subjects and 0.64mmol/l 
(0.02-1.4mmol/l) after eradication (p<0.001) (Fig. 7). Though there was 
considerable overlap between the two groups in respect of their urea and 
ammonium concentrations there was complete separation of the groups 
when the urea: ammonium ratio was considered. The median ratio in
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Figure 7
Urea and ammonium concentrations (mmol/l) and the urea: ammonium ratio 
in gastric juice, samples from subjects before and after eradication of 
Helicobacter pylori.
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gastric juice of infected subjects was 0.26 (0.04-0.7) compared with 3.4 
(1.1-113) in those cleared of the infection (p<0.001). Thus, all subjects 
with H. pylori infection had a ureaiammonium ratio of less than 0.8 and all 
those in whom the infection had been eradicated had a ratio of more than 
1.0 .
In those with the infection, there was no correlation of the area under 
the two hour breath test values curve and the gastric urea concentration, 
ammonium concentration, or urea: ammonium ratio (Fig. 8).
5.4 EFFECT OF H2 RECEPTOR ANTAGONISTS
In the 10 patients studied before and after seven days’ ranitidine 
treatment, there was no change in the gastric juice concentrations of urea 
and ammonium or in their ratio (Table 2). Taking ureaiammonium ratios 
of 0.8 or below as indicative of infection, the H2 antagonist treatment did 
not change the H. pylori classification of any of the subjects.
5.5 DISCUSSION
The unusually high urease activity of H. pylori has been used to rapidly 
detect the presence of the organism in the gastric antral mucosa in several 
different ways. The 14C urea breath test relies on the detection of exhaled 
radio-labelled C 0 2 formed during the hydrolysis of urea. This test is 
reproducible and is regarded as a sensitive method of detecting infection 
of the antral mucosa with the organism (Bell et al 1987, Marshall et al 
1988). However, it does have several disadvantages. The collection of 
the breath samples takes 2 h to complete using the standard protocol 
although a shortened breath test relying on a 40 min breath sample has 
been proposed (Weil and Bell 1989). Our data indicates that the higher 
value of the 10 min and 20 min value can distinguish between those with 
the infection from those in whom it has been eradicated. This would allow
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Figure 8
Correlation of the area under the 120 minute breath test curve
(% dose/mmol COJtg body weight x min) with the urea: ammonium ratio in 
gastric juice (r=0.004).
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Pre-Treatment During Ranitidine Treatment
H. pylori Ammonium Urea Ratio Ammonium Urea Ratio
-ve Patients
1 2.0 2.9 1.4 1.9 2.6 1.3
2 2.2 3.1 1.4 2.9 2.6 0.9
3 2.0 4.3 2.1 2.5 3.0 1.2
4 0.8 2.2 2.6 2.0 2.7 1.3
5 1.6 2.5 1.6 2.8 3.0 1.1
6 1.4 2.0 1.4 1.2 1.9 1.6
7 2.2 2.1 0.9 2.5 2.6 1.0
H. pylori 
+ve Patients
1 6.1 1.2 0.2 5.7 1.4 0.2
2 8.8 2.0 0.2 5.2 1.6 0.3
3 7.2 0.6 0.1 8.4 0.2 0.1
TABLE 2: EFFECT OF 7 DAYS TREATMENT WITH RANITIDINE 
300mg NOCTE ON THE CONCENTRATIONS OF UREA 
AND AMMONIUM AND THEIR RATIO IN GASTRIC JUICE.
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the test to be performed within 30 min. Unfortunately, the analysis of the 
breath samples is also time consuming making it difficult to obtain the 
result on the same day. The breath test involves the administration of a 
small dose of radioactivity which might make the test unsuitable for the 
investigation of children and premenopausal women and for multiple 
studies. The 13C urea breath test eliminates the risk of administering a 
radioisotope but because mass spectrometry is required for the detection of 
13C C02 is unlikely to be introduced into general use (Graham et al 1987).
The rapid urease (CLO-test) uses the change in colour of a pH indicator 
dye in response to the urease activity in a biopsy sample when inserted 
into the gel to detect the organism. The colour change in the gel usually 
takes 3 hr to complete but may take up to 24 hr. The disadvantages of this 
test are that an antral biopsy is required and the investigator is also 
required to remember to read the gel at the correct time. Again, one 
cannot rely on having the result on the same day as the test is performed.
We have found that the urease activity of the organism results in low 
gastric juice urea concentrations and raised gastric juice ammonia 
concentrations. The inverse relationship between the concentrations of 
those two analytes in gastric juice of those with the organism means that 
their ratio allows the clear separation of patients with the infection from 
those in whom it has been eradicated. In those with the infection there 
was no correlation between the urease activity assessed by the urea breath 
test and the concentrations of either urea or ammonia or of their ratio in 
gastric juice. This may be explained by the rate of ammonia production in 
infected individuals being mainly dependent on the availability of urea. 
We have previously noted that intragastric infusion of urea results in a 
marked increase in the ammonia concentration in gastric juice indicating 
that it is the substrate availability which determines the ammonia 
production (Chittajallu et al 1991).
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Finally, the concentration of urea in gastric juice of patients with the 
organism may, on occasion, be below the detection limit for accurate 
determination.
The analysis of the concentrations of ammonium and urea in gastric 
juice could be completed more rapidly than either the urea breath test or 
the rapid urease test. With modem analytical equipment the measurement 
of their concentrations in a sample of gastric juice obtained at endoscopic 
examination might be completed within 10 to 15 minutes. Our studies 
indicate that dosing with the H2 antagonist ranitidine on the evening before 
the endoscopic examination does not alter the discriminating value of the 
urea: ammonium ratio or indeed the concentrations of urea and ammonium 
in gastric juice.
In conclusion, these studies indicate that H. pylori markedly increases 
the concentration of ammonia in gastric juice and this avid production of 
ammonia may be involved in the production of H. py/<?n-related 
hypergastrinaemia. In addition, we have shown that the measurement of 
the ratio of the concentrations of urea and ammonium in gastric juice 
samples from fasted subjects provides a simple method of determining the 
H. pylori status of duodenal ulcer patients.
63
CHAPTER SIX
THE ROLE OF AMMONIA IN THE PATHOGENESIS OF THE 
GASTRITIS, HYPERGASTRINAEMIA AND 
HYPERPEPSINOGENAEMIA I CAUSED BY 
HEUCOBACTER PYLORI INFECTION
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6.1 INTRODUCTION
It is now generally acknowledged that Helicobacter pylori (H. pylori) 
infection is the major cause of antral gastritis (McNulty 1989). However, 
the bacterium does not penetrate the gastric epithelium and the mechanism 
by which it induces inflammation of the underlying mucosa is unknown. 
The organism has very high urease activity (Marshall & Langton 1986) 
and it has been suggested that the production of high concentrations of 
ammonia at the epithelial surface could cause mucosal damage (Murakami 
et al 1988). Though the acidic gastric juice will rapidly convert ammonia 
to less toxic ammonium ions, the high pH at the site of ammonia 
production underneath the mucus layer could allow it to remain in its 
unionised noxious state predispose to mucosal damage by denaturing the 
structure of the protective mucus layer (Sidebotham & Baron 1990).
H. pylori infection has also been shown to increase the serum 
concentration of gastrin and pepsinogen I (Oderda et al 1989, Chittajallu et 
al 1992). Levi et al proposed that the hypergastrinaemia was related to 
bacterial ammonia production raising antral surface pH (Levi et al 1989), 
but studies from our own group do not support this (Chittajallu et al 1991, 
Nujumi et al 1991, Chittajallu et al 1991, Chittajallu et al 1992, McColl et 
al 1992).
In order to investigate the role of ammonia in the histological and 
biochemical changes accompanying H. pylori infection we have examined 
patients with chronic renal failure. The high in tragastric  urea 
concentrations in such patients greatly increases H. pylori ammonia 
production which should accentuate any ammonia-related effects.
6.2 PATIENTS AND METHODS
Gastric juice ammonium concentration, antral histology, and serum 
concentrations of gastrin and pepsinogen I were examined in 9 H. pylori
positive and 9 H. pylori negative normal uraemic patients. These results 
were compared with those from age and sex matched control patients with 
normal renal function with (n=9) and without (n=9) H. pylori infection. 
Each of the patients examined had been referred for upper gastrointestinal 
endoscopy on account of dyspeptic symptoms. None of the patients was 
receiving antibiotic therapy or had taken acid-inhibitory agents within the 
previous week. In addition none of the patients had been treated with 
bismuth preparations, antibiotic therapy or had taken acid inhibitory 
agents within the previous week.
The median age of the H. pylori positive uraemic patients was 51 years 
(range 34-73) compared with 49 years (range 27-67) in those uninfected. 
Three of the H. pylori positive patients were on m aintenance 
haemodialysis, four on continuous ambulatory peritoneal dialysis and two 
had not yet commenced dialysis. One of the H. pylori negative patients 
was on maintenance haemodialysis and eight on continuous ambulatory 
peritoneal dialysis. The median duration of dialysis was similar in the 
H. pylori positive (15 months, range 0-100) and negative (20.5 months, 
range 0-142) patients.
All patients were examined between 0900h and llOOh after an 
overnight fast. Upper gastrointestinal endoscopy was performed after a 
venous blood sample had been removed for determination of serum 
concentrations of urea, gastrin and pepsinogen I. Immediately after 
passing the instrument 10ml of gastric juice was collected by means of a 
trap in the suction line. Following inspection of the upper gastrointestinal 
tract, two biopsies were taken from the greater curvature of the antrum 
2cm from the pylorus.
The H. pylori status of patients and controls was determined by 
microscopy of antral biopsy for Helicobacter-like organisms, rapid urease 
slide test (CLO test) of antral biopsy (Marshall et al 1987), and 14C-urea
breath test. These tests have been shown to be reliable in detecting H. 
pylori infection in patients with and without renal failure (Nujumi et al 
1991).
ANALYSES
In the patients with chronic renal failure the pH of the gastric juice was 
determined using a combined glass electrode (Radiometer ETS 822) prior 
to storage at -20°C. Gastric juice urea and ammonium concentrations 
were determined in all subjects. For this the samples were thawed and 
centrifuged at 3000g for 10 min to remove the mucus. The concentration 
of ammonium was measured in the supernatant following dilution in 0.2M 
phosphate buffer pH 7.4, using an enzymatic method (Sigma, Dorset, 
U.K.) adapted for the Cobas Bio (Roche, Welwyn Garden City, U.K.) as 
previously described (Neithercut et al 1991).
The antral biopsies were fixed in formalin and processed routinely. 
Paraffin sections were cut at three levels and stained with haematoxylin 
and eosin. An extra section from level two was stained with Cresyl Fast 
Violet for detection of H. pylori (Burnett et al 1987). They were examined 
by a single pathologist (S.D.) unaware of their clinical details. The 
severity of antral gastritis was scored using the method of Rauws et al 
(1988) and which we have found to be a sensitive method for assessing the 
severity of H. pylori-induced gastritis (McColl et al 1991, Chittajallu et al 
1991, Neithercut et al 1991). Chronic inflammatory infiltrate in the 
lamina propria was scored as 0, 1 or 2, lamina propria polymorph infiltrate 
as 0, 1, 2 or 3 intra-epithelial polymorph infiltrate as 0, 1, 2 or 3 and 
mucosal erosions as 0,1, or 2. The scores for these individual components 
of H. pylori-relaiQd gastritis are then added to give a cumulative gastritis 
score ranging from 0-10.
The intra-observer variation in the scoring of the severity of the
gastritis was assessed. This was performed by randomly selecting 15 
slides scored by the pathologist (S.D.) at least one year earlier and having 
him rescore them unaware that he had previously examined them. The 
mean cumulative gastritis score for the group of 15 slides was 3.2 (range 
0-6) when first scored compared with 3.3 (range 0-8) when rescored. The 
mean absolute difference in the cumulative gastritis score between the two 
assessments was 0.66 (range 0-2) and the co-efficient of variation was 
21%. This indicates that our pathologist would have a greater than 95% 
chance of detecting a difference in mean cumulative gastritis score of 1 
when comparing two groups of nine subjects.
The serum gastrin concentration was determined by radioimmunoassay 
using antibody R98 (Ardill 1973). This detects both G17 and G34 and 
uses G17 as standard. Serum pepsinogen I was measured using 
commercial radioimmunoassay kits obtained from Incstar Ltd. (Berkshire).
Statistical significance of differences between groups was assessed by 
the Mann Whitney U test.
The study was approved by the Western Infirmary Ethical Committee 
and all patients gave written, informed consent.
RESULTS
The serum urea concentration was elevated to a similar extent in the 
renal failure patients with (median 20mmol/l, range 12-31) or without (23, 
11-32) H. pylori infection (normal range 2.5 - 7.5mmol/l).
The median (range) gastric juice ammonium concentration in the H. 
pylori positive uraemic patients was 19mmol/l (11-43) which was 
approximately four-fold greater than that in the H. pylori positive 
non-uraemic patients (5, range 1-11) (p < 0.005) (Fig. 9). Gastric juice 
ammonium concentrations were similar in the H. pylori negative uraemic 
patients (median 3, range 0.5-11) and H. pylori positive non-uraemic
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Figure 9
Effect of uraemia and Helicobacter pylori (HP) status on intragastric 
ammonium concentrations. * Indicates higher than H. pylori -ve non-uraemic 
patients at p<0.02. ^Indicates higher than the H. pylori +ve non-uraemic 
patients at p<0.005.
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patients (5, range 1-11) (p = 0.2), and both were significantly higher than 
the values for the H. pylori negative non-uraemic patients (0.7, range 
0.1-1.4) (p < 0.02 for each). Intragastric pH was similar in the H. pylori 
positive and negative uraemic patients, with a median value of 3.0 (range 
1.0 - 7.1) in the former and 2.1 (1.2 - 6.6) in the latter.
In spite of the marked difference in in tragastric  ammonium 
concentration, the severity of histological gastritis was similar in the H. 
pylori positive patients with (median cumulative gastritis score = 5, range 
3-6) or without (5, range 3-7) renal failure (Fig. 10). Combining the H. 
pylori positive patients with and without renal failure provided a wide 
range of gastric juice ammonium concentrations (1-43 mmol/1) but there 
was no correlation between this and the severity of the H. py/on-related 
antral gastritis (Table 3). In spite of the H. pylori negative uraemic 
patients having intragastric ammonium concentrations similar to the H. 
pylori positive non-uraemic patients, the former had cumulative gastritis 
scores of 1 or less which was equivalent to those in the H. pylori negative 
patients with normal renal function.
There was no difference in the endoscopic appearance of the upper 
gastrointestinal tract in the renal failure patients with and without H. pylori 
infection. Of the 9 H. pylori positive uraemic patients, two had 
oesophagitis, two had scattered petechiae in the stomach and duodenum, 
and one had erosive duodenitis. Of the 9 H. pylori negative uraemic 
patients, two had oesophagitis, and one had scattered petechiae in stomach 
and duodenum. Endoscopy in the 9 H. pylori positive non-uraemic 
patients showed oesophagitis in one patient and active duodenal ulcer in 
another. In the 9 H. pylori negative non-uraemic patients one had erosive 
duodenitis and another a deformed duodenum.
The median serum pepsinogen I concentration (ng/ml) was higher in 
the H. pylori positive uraemic patients (352, range 280-653) than in the
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Figure 10
Cumulative antral gastritis scores in patients with and without chronic renal 
failure and of different Helicobacter pylori status.
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DESCENDING ORDER OF GASTRIC JUICE AMMONIUM CONCENTRATION.
Gastric Juice Chronic Lamina Propria Intra-Epithelial Lamina Propria Epithelial CUMULATIVE
Ammonium Renal Chronic Polymorph Polymorph Erosions GASTRITIS
(mmol/1) Failure Infiltrate Infiltrate Infiltrate Score SCORE
Score Score Score (0-2) (0-10)
(0-2) (0-3) (0-3)
43 + 2 1 1 0 4
30 + 2 1 2 0 5
21 + 2 2 1 0 5
20 + 2 2 2 0 6
19 + 2 2 1 0 5
19 + 2 2 2 0 6
16 + 1 1 1 0 3
14 + 2 2 2 0 6
11 + 1 1 1 2 5
11 - 2 2 1 0 5
10 - 2 2 2 1 7
8 - 2 1 2 0 5
7 - 2 0 1 0 3
5 - 2 1 2 0 5
5 - 2 1 1 0 4
4 - 2 1 2 0 5
3 - 2 2 2 0 6
1 - 2 2 2 0 6
TABLE 3: GASTRIC JUICE AMMONIUM CONCENTRATIONS AND
ANTRAL GASTRITIS SCORES IN THE H. PYLORI POSITIVE 
INDIVIDUALS WITH (+) AND WITHOUT (-) CHRONIC RENAL 
FAILURE. THEY ARE LISTED IN DESCENDING ORDER OF 
GASTRIC JUICE AMMONIUM CONCENTRATION.
H. pylori negative uraemic patients (165, range 86-337) (p < 0.01) and 
both these groups had higher values than the non-uraemic patients of 
corresponding H. pylori status (p < 0.05 for each) (Fig. 11). Serum 
pepsinogen I values were similar in the non-uraemic patients with (median 
= 103, range 40-170) or without (92, 35-127) H. pylori infection (p = 0.3). 
There was no relationship between the serum pepsinogen I concentration 
and type of renal replacement treatment.
The median serum gastrin concentration (pmol/1) in the non-uraemic 
patients was higher in those with H. pylori (17, range 7-24) than in those 
without the infection (10, range 7-14) (p < 0.05) (Fig. 12). Compared 
with these non-uraemic patients, the gastrin concentrations were markedly 
elevated in the uraemic patients and there was no difference between the 
latter patients with (median = 95, range 52-333) or without (114, range 
47-533) H. pylori infection. There was no relationship between the serum 
gastrin concentration and type of renal replacement treatment.
DISCUSSION
This study demonstrates that the gastric juice ammonium concentration 
is markedly affected by both uraemia and H. pylori infection. The grossly 
elevated intragastric ammonium concentration in the renal failure patients 
with H. pylori infection can be explained by the combination of their high 
gastric juice urea concentration (Lieber & Lefeure 1959) and the high 
urease activity of the organism. We have previously demonstrated that the 
intragastric production of ammonia by H. pylori is controlled by the 
availability of urea in gastric juice (Chittajallu et al 1992).
The reason for the gastric juice ammonium concentration being higher 
in the H. pylori negative uraemic patients than in the H. pylori negative 
non-uraemic patients is not clear. However, a variety of urease producing 
bacteria are present in the mouth and swallowed in the saliva (Bowden et
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Figure 11
Serum pepsinogen I concentrations in patients with and without chronic 
renal failure and of different Helicobacter pylori HP status. ^Indicates higher 
than non-uraemic patients of corresponding H. pylori status at p<0.05. 
**Indicates higher than H. pylori status at p<0.05. **Indicates higher than 
H. pylori -ve uraemic patients at p<0.001.
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Figure 12
Effect of chronic renal failure and HtUcobader pylori (UP) status on fastine 
serum gastrin concentrations. *Indicates higher than H. pylori -ve 
non-uraemic patients at p<0.05.
al 1979). Though such bacteria have lower urease activity than H. pylori, 
they may produce significant amounts of ammonia in the presence of high 
gastric juice concentrations of urea. In addition, it is possible that the high 
gastric juice urea concentration encourages the colonisation of the upper 
gastrointestinal tract by urease positive organisms. We have previously 
observed that H. pylori negative uraemic patients have higher urease 
activity assessed by the 14C-urea breath test than H. pylori negative 
non-uraemic patients (Nujumi et al 1991).
Some in vitro and experimental animal studies have suggested that the 
antral gastritis induced by H. pylori may be caused by the ammonia 
produced by the organism’s high urease activity (Murakami et al 1988, 
Smoot et al 1990, Xu et al 1990, Hazell 1990). Murakami et al showed 
that ammonia produced by the administration of urea plus urease to rats 
can cause microscopic injury to their gastric mucosa (Murakami 1988). In 
vitro studies by Smoot et al demonstrated that ammonia produced by H. 
pylori is cytotoxic to cultures of human gastric epithelial cells (Smoot et al 
1990, Xu et al 1990) and similar studies by Xu et al found that H. pylori 
ammonia production causes vacuolization of Vero cell lines (Xu et al 
1990). In addition to a direct toxic effect of ammonia, it has been 
proposed that ammonium ions may interact with neutrophil-produced 
hypochlorous acid to produce the highly toxic mono-N-chloramine, 
NH2C1 (Hazell 1990). It has also been proposed that H. pylori ammonia 
production will lead to mucosal damage by denaturing the protective 
mucus layer (Sidebotham & Baron 1990). In spite of the findings with 
animal models and in vitro experiments, the present study does not support 
a role for ammonia production in the causation of the antral gastritis in 
man. This was demonstrated by the absence of any correlation between 
the severity of the gastritis or epithelial surface damage and the bacterial 
ammonia production. Examining patients with and without uraemia
enabled us to look at the gastric mucosal damage over a very wide range 
(43 fold) of in vivo ammonia production making it unlikely that any 
association was missed. The abnorm alities related to ammonia 
administration noted in the earlier in vitro studies and animal models may 
be explained by the high pH employed which would have increased the 
proportion of unionised ammonia.
Triebling et al have recently claimed that ammonia production does 
play a pathogenic role in the development of H. py/ori-related gastritis in 
man (Triebling et al 1991). However, this conclusion is not supported by 
their own data. They measured gastric juice ammonium and the severity 
of gastritis in 5 patients with chronic renal failure and H. pylori, before 
and after treatment with ampicillin, and in 5 uninfected patients with renal 
failure. A positive correlation was observed between the gastric juice 
ammonium and severity of gastritis. This correlation, however, can be 
explained simply by the presence or absence of H. pylori in their patient 
group and does not provide evidence of a causal association between H. 
pylori ammonia production and gastritis. Within their small group of 5 
patients with H. pylori there was no correlation between gastric juice 
ammonium and severity of gastritis which is consistent with the findings 
of our present study in which we examined 18 such patients. Our 
conclusion that ammonia does not play a pathogenic role in the 
development of H. py/on-related gastritis in man is also consistent with 
the recent ultrastructural studies by Thomsen et al (1990). They noted that 
there was no correlation between the location of the organism and the 
morphological damage to adjacent epithelial cells or the degree of 
subjacent inflammatory cell infiltrate.
The markedly elevated serum pepsinogen I concentration in the 
patients with chronic renal failure is consistent with previous reports 
(Samloff et al 1975) and can be explained by its impaired renal clearance
(Waldrum 1982). The elevation of serum pepsinogen I was particularly 
marked in the renal failure patients with H. pylori with its concentration 
being double that in the renal patients without the infection. It has 
previously been reported that H. pylori infection raises serum pepsinogen I 
in non-uraemic patients but only by about 25% (Oderda et al 1989, 
Chittajallu et al 1992). The fact that H. pylori infection raises serum 
pepsinogen I to a greater extent in uraemic than non-uraemic subjects 
would be consistent with bacterial ammonia production raising the serum 
concentration of the zymogen. However, little is known about the 
mechanism by which pepsinogen I reaches the serum or about the 
mechanism of its renal excretion. If it is excreted by a saturable process 
then in patients with renal failure the same degree of increased delivery of 
pepsinogen I into the serum could produce a more marked increase in its 
serum concentration.
As previously reported, the serum gastrin concentration was found to 
be elevated in the renal failure patients compared to those 
with normal renal function (Muto et al 1985, El Ghonaimy et al 1981, 
Wesdrop et al 1981, Ala-Kailan et al 1989). Serum gastrin concentration 
is also known to be raised in patients with H. pylori infection (Oderda et al 
1989, Levi et al 1989, McColl et al 1991, Graham et al 1990, Smith et al 
1990) and this is seen in the non-uraemic patients in the present study. It 
has been suggested that the hypergastrinaemia induced by H. pylori is due 
to the ammonia produced by its urease raising antral surface pH and 
thereby blocking the suppression of gastrin release by luminal acid (Levi 
et al 1989). However, we have previously found that neither increasing 
(Chittajallu et al 1991) inhibiting (Nujumi et al 1991) nor completely 
abolishing (Chittajallu et al 1990) H. pylori urease activity in man alters 
serum gastrin. We have also found that H. py/oW -related 
hypergastrinaemia cannot be explained by ammonia altering mucosal
surface pH (Chittajallu et al 1992, McColl et al 1992). The finding that 
the gastrin concentration is similar in the H. pylori positive and negative 
uraemic patients despite the much higher rate of ammonia production in 
the former is further evidence against the hypergastrinaemia being due to 
bacterial ammonia production.
Ala-Kaila et al recently observed that patients with chronic renal failure 
could be divided into two statistically distinct groups according to their 
degree of hypergastrinaemia (Ala-Kaila et al 1989). The differences in 
gastrin could not be explained by differences in acid secretion or severity 
of renal failure and they postulated an unknown mechanism causing 
enhanced synthesis of gastrin. The present study indicates that H. pylori 
infection is not the unknown factor.
In conclusion, this study demonstrates that the very high rate of H. 
pylori ammonia production in uraemic patients is not associated with more 
marked gastritis or hypergastrinaemia. These findings support our 
previous work that H. pylori release of ammonia is unlikely to be 
responsible for either the hypergastrinaemia or the gastritis caused by this 
bacterium.
CHAPTER SEVEN
EFFECT OF INHIBITION OF HEUCOBACTER PYLORI 
UREASE ACTIVITY BY ACETOHYDROXAMIC 
ACID ON SERUM GASTRIN IN 
DUODENAL ULCER PATIENTS
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7.1 INTRODUCTION
Eradication of Helicobacter pylori infection of the gastric antrum 
results in a lowering of the circulating gastrin concentration (Oderda et al 
1989, McColl et al 1989, Levi et al 1989, Graham et al 1990, Chittajallu et 
al 1991). The fasting concentration falls by 27%-33% and the integrated 
gastrin response to a meal by 30-58%. This stimulation of gastrin release 
by H. pylori may be relevant to the role of the organism in duodenal ulcer 
disease. The mechanism by which chronic infection of the antral mucosa 
with H. pylori results in increased gastrin release is not known.
H. pylori is remarkable because of its high urease activity by which it 
hydrolyses urea to ammonia and carbon dioxide (Marshall & Langton 
1986). As a result of this, patients w'ith the infection have reduced 
concentrations of urea and increased concentrations of ammonium in their 
gastric juice (Chittajallu et al 1991). The production of ammonia by the 
bacterium at the antral epithelial surface could increase gastrin release by 
any of three theoretical mechanisms. Ammonia is a strong alkali and 
could therefore prevent the physiological inhibition of gastrin release by 
gastric acid (Walsh et al 1975). In addition, elevation of antral surface pH 
by ammonia would facilitate the entry of dietary amines into the antral G 
cells and thereby their stimulation of gastrin release (Lichtenberger et al 
1986). Thirdly, ammonia could directly stimulate gastrin release as has 
been shown to occur in the rat (Lichtenberger et al 1982).
In an attempt to elucidate the mechanism of the hypergastrinaemia 
associated with H. pylori infection, we have examined the effect of 
inhibiting the bacterium’s urease activity and ammonia production on 
serum gastrin in duodenal ulcer patients.
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7.2 PATIENTS AND METHODS
7.2.1 STUDIES IN PATIENTS WITH H. PYLORI INFECTION
Six patients confirmed endoscopically to have duodenal ulceration 
within the previous year but currently in clinical remission were studied. 
Their median age was 39 years (range 26-52) and three were females. In 
each patient, antral biopsy obtained endoscopically within the preceding 
three months had shown gastritis associated with H. pylori-like organisms.
The patients reported fasted and a venous blood sample was removed at 
0800 hours for gastrin determination. Immediately following this, they 
drank 50ml water and further blood samples were taken at 30 min 
intervals over the following 2 hours. At 1000 h they took a standard meal 
consisting of 2 beef cubes (OXO Ltd., Croydon, England) dissolved in 200 
ml water at 50°C. Further blood samples were taken at 10 minute intervals 
for 70 minutes and a final one at 90 minutes following the OXO drink. 
Immediately following this sample a 14C-urea breath test was performed to 
measure H. pylori urease activity. For this they drank 250 ml Ensure Plus 
(Abbott Laboratories, England) to delay gastric emptying followed by 0.4 
MBq 14C-urea (Amersham International) in 25 ml water. Breath samples 
for 14C-C02 analysis were obtained at 10 min intervals for 90 mins.
On the following day, the study was repeated in an identical fashion 
except that the patients received 750 mg acetohydroxamic acid (Lithostat, 
Mission Pharmacol, U.S.A.) with a 50 ml drink of water at 0800 hrs.
Ten days later a third 14C-urea breath test was performed to determine 
whether the temporary inhibition of urease activity had resulted in 
clearance of the infection.
7.2.2 STUDIES IN PATIENTS WITHOUT H. PYLORI INFECTION
Two male patients (aged 25 and 52 years) with a past history of 
duodenal ulcer disease, but in whom H. pylori had been eradicated within
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the previous year, were studied in an identical fashion to that described 
above. This was performed in order to exclude the possibility that 
acetohydroxamic acid might have a direct effect on gastrin release.
7.2.3 STUDY IN HEALTHY VOLUNTEER WITH H. PYLORI INFECTION
The effect of acetohydroxamic acid on the concentrations of urea and 
ammonium in gastric juice was examined in a single healthy volunteer 
(A.N. aged 32 years) with H. pylori infection. Endoscopic antral biopsy 
obtained three months earlier had demonstrated gastritis and H. pylori-like 
organisms. A 14C-urea breath tests performed one month prior to the 
study gave a 30 min value of 109 percentage dose/mmol C 02 x kg body 
wt x 100 which is in the middle of our range for infected subjects 
(35-225).
He reported fasted at 0800 h and a nasogastric tube was passed 
perorally. The resting gastric juice was aspirated and discarded and then 
constant suction applied. At 30 min the suction was temporarily 
discontinued and a 5 ml sample of gastric juice obtained by manual 
aspiration. A further such sample was obtained at 60 min. Immediately 
following this 750 mg acetohydroxamic acid was taken orally with 50 ml 
water and no suction applied until 1 hour later when all the resting volume 
was aspirated and a 5 ml aliquot retained for analyses. Suction was then 
recommenced but temporarily discontinued every 30 min. over the 
following 3.5 hrs to allow manual aspiration of 5 ml samples of gastric 
juice.
7.3 ANALYSES
Gastrin concentrations in serum were determined by a standard 
radioimunoassay kit (C.I.S. U.K. Ltd.). Each patient’s Day 1 and Day 2 
samples were assayed in the same batch. The concentration of urea in 
gastric juice was determined by a prospective analyser (American
Monitor, West Sussex, U.K.) and the concentration of ammonium by an 
enzymatic method (Sigma, Dorset, U.K.). Preliminary studies confirmed 
that acetohydroxamic acid did not interfere with the analysis of urea or 
ammonium in gastric juice. The integrated gastrin response to the OXO 
meal was assessed by calculating the area under the serum gastrin 
concentration time curve using the trapezoid method.
Statistical analysis was performed by means of the Wilcoxon signed 
rank-sum test. The study was approved by the Western Infirmary Ethical 
Committee and each patient gave written informed consent.
RESULTS
The excretion of 14C-C02 in the breath was markedly lower following 
the administration of acetohydroxamic acid (Fig. 13). On the first study 
day, the median 30 min breath test value was 152 percentage dose/mmol 
C 02 x kg body wt x 100 (range 111-335) compared with 22 (range 14-95) 
following acetohydroxamic acid (p < 0.03). The median value 10 days 
after the administration of acetohydroxamic acid was 149 (range 126-257) 
which was similar to the pre-treatment value (Fig. 14).
In spite of the marked suppression of H. pylori urease activity, there 
was no difference between the two study days with respect to the basal or 
meal-stimulated serum gastrin concentrations (Fig. 15). The median 
integrated gastrin response to the OXO meal was 78 ng/l.h (range 21-222) 
on Day 1 and 79 (range 33-207) on Day 2 (Fig. 16).
In the two patients without H. pylori infection their basal and 
m eal-stim ulated gastrin levels were also unaffected by the 
acetohydroxamic acid.
In the healthy volunteer with H. pylori infection the administration of 
acetohydroxamic acid resulted in a rise in the urea concentration and a fall 
in the ammonium concentration in gastric juice (Fig. 17). This was
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evident in the first sample of juice which was collected one hour following 
the administration of the urease inhibitor and persisted for the full 3.5 
hours studied. The ammonium concentrations in gastric juice prior to the 
inhibitor were 5.2 and 5.5 mmol/1 and following the inhibitor ranged from
1.9-3.6 mmol/1. The ratio of urea/ammonium in gastric juice prior to the 
urease inhibitor was 0.2 whereas 5 of the 6 following the inhibitor were 
more than 1.0.
None of the patients experienced any side-effects following the 
administration of acetohydroxamic acid.
DISCUSSION
Acetohydroxamic acid is a specific urease inhibitor which has been 
used to reduce bacterial ammonia production in patients with renal calculi 
secondary to chronic urinary tract infection (Williams et al 1984). 
Reducing the ammonia production lowers the pH of the urine and thereby 
lessens the tendency for calculi formation. In this situation the drug has 
been prescribed in a dose of 250mg four times a day. We administered the 
drug as a once-off dose of 750mg in order to achieve rapid and effective 
inhibition of urease activity.
Inhibition of H. pylori urease activity was demonstrated by the 5-fold 
reduction in the 30 minute values of the 14C-urea breath test. The 
concentrations of urea and ammonium in the gastric juice of the volunteer 
also confirmed inhibition of urease activity. We have previously noted 
that though there is overlap of H. pylori negative and positive subjects 
with respect to their gastric ju ice ammonium concentration, the 
urea/ammonium ratio in gastric juice provides clear separation of the two 
groups (Neithercut et al 1991). The median urea/ammonium ratio prior to 
the urease inhibitor was 0.2 which is within our range for infected subjects 
(0.04-0.7), and that follow ing adm inistration of the inhibitor
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was 1.2 which is just within our range for patients eradicated of the infection 
(1.1-113). The finding of altered urea and ammonium concentrations in 
the first sample of juice examined and its persistence throughout the 
remainder of the 3.5 hours observed is consistent with the fact that 
acetohydroxamic acid is rapidly absorbed from the upper gastrointestinal 
tract reaching peak plasma concentrations at 60 minutes and with a plasma 
half-life of 3.5-5 hours (Feldman et al 1978). It is not clear whether the 
inhibition of H. pylori urease activ ity  by orally adm inistering 
acetohydroxamic acid is due to a topical or systemic effect or both.
In spite of the suppression of H. pylori urease activity there was no 
accompanying fall in the basal gastrin concentration or in the gastrin 
response to the OXO meal. There was also no change in gastrin 
concentration in the H. pylori negative subjects which excluded the 
possibility that a fall in gastrin in those with the infection had been masked 
by a direct gastrin stimulating effect of the drug.
It has been proposed that the hypergastrinaemia in patients with H. 
pylori infection is due to the ammonia produced by the bacterium raising 
antral surface pH (Levi et al 1989). This would prevent the physiological 
suppression of gastrin release by in tragastric  acid, resulting in 
inappropriate release of the hormone. If this were the mechanism of the 
hypergastrinaemia, the gastrin level should fall rapidly following 
inhibition of bacterial urease activity. In patients with hypergastrinaemia 
secondary to achlorhydria the gastrin falls within 5-15 minutes of 
intragastric instillation of hydrochloric acid (Yalow and Berson 1970). 
Likewise, in healthy subjects the intragastric administration of acid at the 
same time as a meal markedly suppresses or abolishes the gastrin response 
to the meal (Walsh et al 1975). The lack of a fall in serum gastrin even 3.5 
hours after suppression of urease activ ity  indicates that the 
hypergastrinaemia is unlikely to be due to disruption of the acid-inhibitory
91
feedback mechanism by bacterial ammonia. However, we cannot exclude 
the possibility that the degree of inhibition of urease activity with the 
acetohydroxamic acid might have been insufficient to allow restoration of 
the acid-inhibitory mechanism.
We have previously reported that increasing H. pylori ammonia 
production three-fold for four hours by intragastric infusion of urea does 
not raise serum gastrin (Chittajallu et al 1991). The present finding that 
inhibition of H. pylori ammonia production does not lower serum gastrin 
provides further evidence against the hypergastrinaemia being directly 
linked with bacterial urease activity.
Other mechanisms to explain the hypergastrinaemia need to be 
considered. It could be related to the chronic inflammatory cell infiltrate 
which the infection induces in the underlying antral mucosa where the G 
cells are located. Studies using isolated perfused canine antrum have 
shown that the T lymphocyte products interleukin  -2 and 
gamma-interferon stimulate gastrin release (Teichmann et al 1986). 
Recent observations by Wyatt et al indicate that hypergastrinaemia 
correlates more closely with inflammation of the antral mucosa than with 
infection with H. pylori (Wyatt et al 1989).
This study also demonstrates that normal urease activity is not essential 
for H. pylori to survive within the human stomach. It has been suggested 
that the organism produces ammonia in order to create an alkaline 
micro-environment and thus shield itself from the acidic gastric juice 
(Goodwin et al 1986). In spite of marked suppression of urease activity 
the infection was not cleared in any of our patients as shown by the repeat 
breath test 10 days later. Ammonia production may be important in 
protecting the bacterium from luminal acid when the organism is first 
ingested but less important when the infection becomes established in the 
less acidic environment of the deep mucus layer.
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CHAPTER EIGHT 
HEUCOBACTER PYLORI AND HYPERGASTRINAEMIA DURING 
PROTON PUMP INHIBITOR THERAPY.
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8.1 INTRODUCTION
Most acid inhibitory agents increase the circulating concentration of 
gastrin (Londong et al 1983, Walan et al 1979, Forrest et al 1979, 
Mahachai et al 1985, Lanzon-Miller et al 1987). This effect is most 
marked with the proton pump inhibitor omeprazole which is the most 
powerful inhibitor of acid secretion currently available (Koop et al 1990, 
Lind et al 1988, Jansen et al 1990, Larsson et al 1988). Jansen et al noted 
that during maintenance treatment with 20mg omeprazole, 25% of their 
patients had fasting gastrin concentrations of more than six times the upper 
limit of normal (Jansen et al 1990). The effects of this degree of 
hypergastrinaemia in man are unclear but animal studies have shown that 
prolonged drug-induced hypergastrinaemia causes ECL cell hyperplasia 
and carcinoid tumours of the stomach and colon (Larsson et al 1988, 
Larsson et al 1986, Havu 1986, Poynter et al 1985). The degree of 
increase in circulating gastrin during omeprazole therapy varies 
considerably from patient to patient and does not correlate closely with the 
degree of acid inhibition (Koop et al 1990, Lind et al 1988). This suggests 
that the gastrin response is influenced by factors other than the degree of 
acid inhibition.
In addition to increasing the serum gastrin concentration, omeprazole 
also increases the serum pepsinogen I concentration (Jansen et al 1990, 
Ten Kate et al 1988, Festen et al 1984). The mechanism of this effect is 
unclear.
We and others have recently demonstrated that the circulating gastrin 
concentration is raised in patients with chronic Helicobacter pylori (H. 
pylori) infection and falls by approximately 50% following eradication 
therapy (McColl et al 1989, Levi et al 1989, Levi et al 1989, Graham et al 
1990, Oderda et al 1989, Smith et al 1990, McColl et al 1991). The 
mechanism by which H. pylori raises serum gastrin is unknown but it has
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been proposed that it is due to its ammonia production elevating antral 
surface pH and thus a similar mechanism to that of proton pump inhibitory 
agents (Levi et al 1989). Chronic H. pylori infection has also been shown 
to raise the serum pepsinogen I concentration (Oderda et al 1989).
In the present study we investigate the influence of chronic H. pylori 
infection on the rise in serum gastrin and serum pepsinogen I during 
treatment with the proton pump inhibitor pantoprazole (SmithKline 
Beecham).
8.2 SUBJECTS AND METHODS
8.2.1 SUBJECTS
Sixteen male patients with a history of endoscopically confirmed 
duodenal ulceration within the previous two years were studied. In 8 of 
them, H. pylori infection had been successfully eradicated 2-14 months 
(median 4 months) prior to entering the present study. This had been 
achieved by four weeks therapy with a combination of tri-potassium 
dicitrato bismuthate (De-Nol tab.) 120mg t.i.d., metronidazole 400mg t.i.d. 
and amoxycillin 250mg t.i.d. The eradication of their H. pylori infection 
resulted in a median fall of 27% in their basal gastrin concentration and of 
46% in their integrated gastrin response to a peptone meal and this data 
has been previously reported (McColl et al 1989, McColl et al 1991).
The two groups of patients of different H. pylori status were similar 
with respect to age and smoking habits. Their H. pylori status was 
confirmed within the month prior to entering the study by histology of 
antral biopsy, rapid urease test (CLO-test) (Marshall et al 1987) and 
14C-urea breath test. All the H. pylori positive patients had 20 minute 
14C-urea breath test values of more than 50 per cent 14C dose per mmol 
C 02 x kg body weight x 100 and those in whom the infection had been 
eradicated had values of less than 15. Each patient discontinued any acid
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inhibitory therapy at least one month prior to entering the study. None of 
them had received any antibiotics or bismuth preparations within the 
previous two months.
8.2.2 DESIGN
Each patient was studied prior to commencing pantoprazole and on the 
fifth day of treatment with 40mg per day. The drug was taken as a single 
daily dose in 100ml water at 0925h which was immediately before 
breakfast. On both study days intragastric pH and serum gastrin 
concentrations were measured. In the 8 patients who were H. pylori 
positive, 14C-urea breath tests were performed 10 days after completing 
the course of therapy to exclude the possibility that the proton pump 
inhibitor had cleared the infection.
The patients reported fasted at 0830h and a combined glass electrode 
(Radiometer, GK2802C) was passed perorally so that its recording tip was 
50cm from the incisor teeth. It was connected to a digital recorder 
(Digitrapper MKII, Synectics Medical) which registers the pH every 4 
seconds. At the start and completion of each recording, the electrodes 
were calibrated using standard buffers.
The content and timing of the meals was identical on each study day. 
Breakfast was taken at 0930h and consisted of 20g Crunchy Nut 
Cornflakes (Kellog Company) with 200ml semi-skimmed milk, one roll 
lightly spread with butter and one cup of tea. At 1300h they had a peptone 
meal consisting of two beef cubes (OXO Ltd., Croydon) dissolved in 
200ml water at 55°C. A further cup of tea was taken at 1545h. Dinner 
was taken at 1800h and consisted of lentil soup with one roll lightly spread 
with butter, followed by Lasagne (447kcal, Marks and Spencer pic) with 
additional whole carrots (Heinz, Middlesex) and a chocolate coated ice 
cream (Safeway Foodstores Ltd., Kent) to finish. They also had a cup of 
tea immediately after dinner and a further cup with a single oat cake
biscuit at 2200h. Patients who smoked recorded the timing and number of 
cigarettes on the first study day and precisely reproduced this smoking 
habit on the subsequent day.
A venous blood sample was taken for fasting serum gastrin 
determination at 0830h which was prior to passing the pH electrode and 
taking the drug. Further samples were taken for determining the 
pre-prandial gastrin concentrations at 1230h, 1245h and 1255h. The OXO 
meal was commenced at 1300h and further samples for gastrin 
determination taken every 15 minutes for 75 minutes.
Serum pepsinogen I concentrations were determined in the fasting 
serum sample and also in the 1245h pre-prandial serum sample. It was not 
determ ined in the post-prandial samples as serum pepsinogen I 
concentration rises only very slightly following eating (Samloff et al 
1975).
The venous blood samples for gastrin and pepsinogen I were placed in 
plain containers and allowed to stand for 15 minutes to allow clotting. 
The serum was then separated by centrifugation at 4°C for 10 minutes and 
stored at -20°C.
8.2.3 INTRAGASTRIC pH ANALYSIS
The intragastric pH data were transferred from the Digitrapper recorder 
to an IBM compatible computer (Amstrad PC 1512 HD20) and analysed 
using the GastrograpH program (Ver 5.0, 1987, Gastrosoft Inc). For each 
patient the median value of all their recordings from 0900h-2300h was 
calculated and called their daytime pH.
8.2.4 BIOCHEMICAL ANALYSIS
Serum gastrin was measured using commercial radioimmunoassay kits 
obtained from CIS (UK) Ltd., (Bucks). The gastrin assay reacted 100% 
with gastrin-17 and 72% with gastrin-34 in molar terms. The minimum
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detection limit of the assay was 20ng/l (CV - 22%) and the interassay CV 
was <10% from 40-700ng/l. All samples for each patient were measured 
in the same batch. The median value of the 3 samples obtained over the 
30 minutes prior to commencing the OXO meal was calculated for each 
patient and called their preprandial gastrin. The highest gastrin 
concentration in response to the OXO meal was called the peak prandial 
gastrin.
Serum Pepsinogen I was m easured using com m ercial 
radioimmunoassay kits obtained from Incstar Ltd. (Berkshire). This assay 
reacted with Group I pepsinogens and had a minimum detection limit of 
lng/ml and an interassay CV of < 10% from 2-30ng/ml. Patient samples 
were diluted 1:10 or 1:20 prior to analysis as appropriate to obtain values 
within the range of the standard curve.
8.2.5 14C-UREA-BREATH TEST
For the 14C-urea breath tests the patients drank 250ml of Ensure Plus 
immediately followed by 0.4MBq 14C-urea (Amersham International) in 
25ml water. Breath samples were collected every 10 minutes for 30 
minutes and analysed as described by Marshall and Surveyor (Marshall & 
Surveyor 1988). The 20 minute value was used as the determinant of the 
urease activity (Bell et al 1987).
8.2.6 STATISTICS
Statistical analysis of differences between the two groups was 
performed using the Mann-Whitney U test and of differences within each 
group by the Wilcoxon’s Signed Rank-Sum Test. The data was expressed 
as medians and ranges because of its non-parametric distribution.
The study was approved by the Western Infirmary Ethics Committee 
and each patient gave informed, written consent
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8.3 RESULTS
The repeat 14C-urea breath tests performed in the H. pylori positive 
patients after completing the 5-day course of pantoprazole were similar to 
the pre-treatment values indicating that the infection had not been 
eradicated in any of these patients by the proton pump inhibitor therapy.
8.3.1 INTRAGASTRIC pH
In the H. pylori eradicated patients their median (range) daytime pH 
rose from 1.9 (1.4 - 2.8) pre-treatment to 3.7 (1.9 - 6.1) on treatment (p = 
0.03) and in the H . pylori positive patients from 1.7 (1.3-2.2) to 4.4 
(3.1-6.2) (p = 0.02). There was no significant difference between the H. 
pylori eradicated and H. pylori positive groups with respect to their 
intragastric pH values either pre-treatment or during treatment.
8.3.2 SERUM GASTRIN
The median serum gastrin concentrations for the H. pylori positive and 
H. pylori eradicated patients before and during treatment are shown in 
Figure 18.
Pre-treatment, the H. pylori positive and eradicated patients did not 
differ significantly with respect to either their fasting or pre-prandial 
gastrin concentrations. However, the pre-treatment median peak prandial 
gastrin concentration (ng/1) was higher in the H. pylori positive patients 
(63 range 42-225) than in the H. pylori eradicated patients (42, range 
30-93) (p < 0.05).
In the H. pylori eradicated patients their median fasting serum gastrin 
concentration rose from 37 (27-43) pre-treatment to 45 (33-52) on 
treatment (p = 0.02), their pre-prandial gastrin from 38 (27-51) to 51 
(36-172) (p < 0.01) and their peak prandial gastrin from 42 (30-93) to 76 
(39-221) (p < 0.01). In the H. pylori positive patients their median fasting 
gastrin concentration was 47 (34-113) pre-treatment and 59 (41-88) on
99
140 -
120 -
100 -
Median
serum 60 -
Gastrin
( n g / l ) 60 -
40 -
20 -
H P eradicated
DRUG 0X 0 MEAL
..... .
11  •....11
t—//—i— i— i— •— i 
0830 1230 1300 1330
— I----- r
1400
DRUG
J i '
H P positive
OXO MEAL /•• . 
t
I— 
0830
— 1----------1 1—
1230 1300
I 1------1------r
1330 1400
TIME TIME
Figure 18
Median serum gastrin concentration before (------) pantoprazole and on the
5th day of treatment ( - - - - )  with 40mg/day in patients with Helicobacter 
pylori infection and in patients in whom it had been eradicated.
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treatment (n.s., p = 0.25). Their pre-prandial gastrin rose form 47 (28-97) 
pre-treatment to 73 (39-285) on treatment (p < 0.01) and their peak 
prandial gastrin from 63 (42-225) to 124 (72-309) (p <0.01) (Figs. 19 and 
20).
The median percentage increase in serum gastrin on treatment was 
similar in the H. pylori eradicated and H. pylori positive patients being 45 
(2-377) and 41 (21-194) respectively for pre-prandial values and 69 
(15-152) and 81 (37-223) for peak prandial values. Consequently, the 
peak prandial concentrations during treatment were significantly higher in 
the H. pylori positive than in the eradicated patients (p < 0.05).
8.3.3 SERUM PEPSINOGEN I
Pre-treatment, there was no significant difference between the H. pylori 
positive and eradicated patients with respect to either their fasting or 
pre-prandial serum pepsinogen I concentrations.
In the H. pylori eradicated patients their median fasting serum 
pepsinogen I concentration (ng/ml) rose from 92 (41-182) pre-treatment to 
121 (53-196) (p = 0.02) on treatment and the pre-prandial values from 
99 (48-142) to 135 (52-197) (p = 0.01). In the H. pylori positive patients 
their median fasting serum pepsinogen I rose from 89 (63-171) to 191 
(115-555) (p < 0.01) and their pre-prandial values from 104 (70-179) to 
191 (125-575) (p < 0.01) (Fig. 21).
The median percentage increase in fasting serum pepsinogen I on 
treatment was greater in the H. pylori positive patient (151, range 23-454) 
than in the H. pylori eradicated patients (29, range -4 to +51) (p < 0.02). 
Likewise, the percentage increase in pre-prandial serum pepsinogen I was 
higher in the H. pylori positive patients (114, range 27-418) than 
eradicated patients (8, range -22 to 203) (p < 0.05). Consequently, during 
treatment the serum pepsinogen I concentrations were significantly higher 
in the H. pylori positive patients than in the eradicated patients (p < 0.05).
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Figure 19
Effect of 5 days therapy with pantoprazole on pre-prandial serum gastrin 
concentrations in the patients with different H. pylori status. ^Indicates 
higher than corresponding pre-treatment values at p<0.01.
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Figure 20
Effect of pantoprazole on peak prandial serum gastrin concentrations in 
patients with different Helicobacter pylori status. ^Indicates higher than 
corresponding pre-treatment values at p<0.01. **Indicates higher than 
values for H. pylori eradicated patients receiving pantoprazole at p<0.05.
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Figure 21
Effect of pantoprazole on pre-prandial serum pepsinogen I concentrations in 
the patients with different H. pylori status. ^Indicates higher than 
corresponding pre-treatment values at p<0.01. **Indicates higher than 
values for H. p^ri-eradicated patients receiving pantoprazole at p<0.05.
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8.4 DISCUSSION
The finding pre-treatm ent of higher m eal-stim ulated gastrin 
concentrations in the H. pylori positive patients is consistent with the 
previous reports that the infection stimulates gastrin release (McColl et al 
1989, Levi et al 1989, Levi et al 1989, Graham et al 1990, Oderda et al 
1989, Smith et al 1990, McColl et al 1991). Levi et al have proposed that 
the increased gastrin concentration stimulates excessive acid secretion and 
thereby explains the link between the infection and duodenal ulcer disease 
(Levi et al 1989). However, this study does not support the hypothesis as 
the increased serum gastrin concentration in the H. pylori positive patients 
was not accompanied by increased intragastric acidity. We have 
previously shown that intragastric pH and nocturnal acid output are 
unchanged even seven months after eradication of H. pylori infection in 
duodenal ulcer patients (McColl et al 1991). The role, if any, of 
hypergastrinaemia in the link between chronic H. pylori infection and 
duodenal ulcer disease is unclear.
One of the side-effects of marked suppression of intragastric acidity 
with proton pump inhibitory agents is the resulting rise in serum gastrin. 
This study has shown that the percentage increase in serum gastrin on 
treatment is similar in H. pylori positive and H. pylori eradicated patients. 
Consequently, patients with H. pylori infection have higher serum gastrin 
concentrations during proton pump inhibitor therapy than similar patients 
in whom the infection has been eradicated.
The findings of this study are relevant to the mechanism by which H. 
pylori infection induces hypergastrinaemia. Levi et al proposed that it is 
due to the ammonia produced by the bacterium’s urease raising antral 
surface pH and thereby preventing the inhibition of gastrin release by 
gastric acid (Levi et al 1989). If the hypergastrinaemia in H. pylori
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infection were due to elevated antral pH then the rise in gastrin induced by 
elevation of intragastric pH by pantoprazole should be less in H. pylori 
positive patients. In other words, if the inhibitory influence of intragastric 
acid on gastrin release is already blocked by H. pylori infection, then 
reducing intragastric acidity with the proton pump inhibitor should have 
little further effect. However, we found that the percentage rise in serum 
gastrin was the same in those with and without H. pylori infection. Our 
finding in this study is consistent with our recent observation that the 
increase in serum gastrin during antral alkalinization is similar in H. pylori 
positive and negative subjects (Chittajallu et al 1992). These findings 
demonstrate that H. pylori hypergastrinaemia cannot be explained by 
elevation of antral surface pH by the bacterium’s urease activity.
The findings of the present study are also consistent with our previous 
studies indicating that H. py/ori-induced hypergastrinaemia is not linked to 
the bacterium’s urease activity. Neither increasing H. pylori ammonia 
production by intragastric infusion of urea (Chittajallu et al 1991) nor 
inhibiting it with acetohydroxamic acid (Nujumi et al 1991), nor 
completely suppressing it with twenty four hours of triple therapy 
(Chittajallu et al 1991), altered the serum gastrin concentration.
Pre-treatm ent serum pepsingogen I concentrations were not 
significantly different in the H. pylori positive and eradicated patients 
though there was a trend in favour of higher values in the latter. Oderda et 
al observed that the mean pepsinogen I concentration fell by 32% after 
eradicating H. pylori in children with a variety of upper gastrointestinal 
disorders (Oderda et al 1989). The mechanism by which the infection 
raises serum pepsinogen I is not known but could be due to the 
accompanying inflammation resulting in leakage of the zymogen from 
chief cells and mucus neck cells. The higher serum pepsinogen I 
concentrations reported in children with H. pylori infection may be
explained by them having a more acute and widespread gastritis involving 
the gastric body where most of the pepsinogen secreting cells are located. 
In the adult duodenal ulcer patients examined in the present study, the 
infection is mainly confined to the gastric antrum.
The observation that the serum pepsinogen I concentration increased on 
pantoprazole is consistent with reports with the other proton pump 
inhibitor omeprazole (Jansen et al 1990, Ten Kate et al 1988, Festen et al 
1984). The mechanism by which treatment with proton pump inhibitors 
raises serum pepsinogen I is unclear. It may be due to passive 
back-diffusion into the systemic circulation resulting from increased 
concentrations of the zymogen in the gastric glands secondary to low 
volume secretion (Ten Kate et al 1988). Our observation that the 
percentage increase in serum pepsinogen I was higher in the patients with 
H. pylori infection is new and the reason for their exaggerated response is 
unclear.
The finding that eradication of H. pylori reduces the hypergastrinaemia 
during proton pump inhibitor therapy has important clinical implications. 
The proton pump inhibitor omeprazole is the most effective medical agent 
for treating severe oesophagitis. However, there is reluctance to maintain 
patients on this therapy because of the potential adverse effects of 
long-term hypergastrinaemia. The present study suggests that eradicating 
H. pylori infection may be a means of reducing hypergastrinaemia in such 
patients. There is no evidence incriminating H. pylori infection in the 
pathogenesis of oesophagitis and therefore eradicating the infection would 
not remove the need for the proton pump inhibitor therapy. Studies are 
required to assess whether the serum gastrin concentration remains lower 
in H. pylori negative patients even during long-term treatment with proton 
pump inhibitors.
CHAPTER NINE
EFFECT OF ERADICATING H. PYLORI 
ON HYPERGASTRINAEMIA 
DURING LONG TERM OMEPRAZOLE THERAPY
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9.1 INTRODUCTION
Hypergastrinaemia is a well recognised side-effect of treatment with 
proton pump inhibitor drugs (Koop et al 1990). This occurs due to the 
marked suppression of gastric acid secretion and thus removal of the acid 
mediated inhibition of gastrin release (Banerjee et al 1995, Lind et al 
1991). The clinical significance of such hypergastrinaemia in patients 
requiring long term proton pump inhibitor therapy is unclear.
In rats, long term omeprazole treatment is associated with argyrophil 
cell hyperplasia within the oxyntic mucosa (Creutzfeldt et al 1986, 
Larsson et al 1988, Koop et al 1987) and the development of gastric 
carcinoid tumours in up to 30% of female animals (Ekmann et al 1985, 
Betton et al 1988). These changes in the rats have been shown to be a 
consequence of the drug induced hypergastrinaemia (Eissele et al 1992). 
In man, long term treatment with omperazole also results in argyrophil cell 
hyperplasia which correlates with the degree of hypergastrinaemia 
(Creutzfeldt et al 1991). Gastrin also exerts trophic effects on gastric and 
colonic mucosa and upon certain carcinoma cell lines derived from these 
tissues (Kusyk et al 1986, Ishizuka et al 1992). The possible role of 
hypergastrinaem ia in the developm ent and growth of certain  
gastrointestinal tumours is uncertain but continues to attract research 
interest (Watson et al 1993, Rehfeld 1995). Due to the uncertainty about 
the clinical significance of long term hypergastrinaemia in man, it would 
seem prudent to minimise the disruption of gastrin physiology induced by 
proton pump inhibitor drugs if possible.
Another common cause of chronic hypergastrinaemia in humans is H. 
pylori infection (Chittajallu et al 1992). This is present in about 50% of 
the adult population Veldhuyzen van Zanten 1994) and in a similar or 
higher proportion of patients who will be prescribed proton pump inhibitor 
drugs for management of their dyspeptic disease. There is little
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information concerning the influence of H. pylori status on the gastrin 
response to proton pump inhibitor therapy. In the present study, we have 
examined this and in particular assessed whether eradicating H. pylori 
infection prior to commencing omeprazole therapy could be a means of 
reducing the hypergastrinaemia during the proton pump inhibitor therapy.
9.2 MATERIALS AND METHODS
9.2.1 PATIENTS
Thirty three patients with endoscopically confirmed disease were 
studied. Their median age was 45 years (range 26-60). Twenty-two were 
males. Their endoscopic diagnosis included duodenal ulcer (20), 
oesophagitis (6), prepyloric ulcer (3), oesophagitis + DU (3), prepyloric 
ulcer + DU (1). Each of the patients had evidence oi H. pylori infection 
confirmed by microscopy of antral biopsy and 14C-urea breath test.
9.2.2 STUDY DESIGN
On entry to the study all patients had their serum gastrin concentration 
assessed fasted and in response to a standardised meal. A 14C-urea breath 
test was performed simultaneously. Any acid inhibitory drugs were 
stopped at least 4 weeks prior to this assessment. Following this they were 
randomised to receive either H. pylori eradication therapy consisting of 3 
weeks treatment with tripotassium dicitratobismuthate 120g t.i.d., 
metronidazole 400mg t.i.d. and amoxycillin 250mg t.i.d. plus gastrocote 
(alginic acid plus aluminium hydroxide plus magnesium trisilicate plus 
sodium bicarbonate, Boehringer Mannheim, Livingstone, U.K.) as 
required for symptoms or gastrocote alone. Four weeks after completing 
this therapy all patients had repeat serum gastrin studies and 14C-urea 
breath test and endoscopic examination.
Subjects then received four weeks treatm ent with omeprazole 
40mg/day followed by six months treatment with omeprazole 20mg/day.
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The doses of omeprazole were taken before breakfast. At the end of the 
one month course of the omeprazole 40mg/day and again the end of the 
six months omeprazole 20mg/day the serum gastrin measurements and 
endoscopic exam ination were repeated. After the 6 months of 
omeprazole 20mg/day the proton pump inhibitor was stopped and patients 
maintained if required on Gastrocote for 4 weeks before having a further 
14C-urea breath test.
9.2.3 COMBINED 14c-UREA BREATH TEST AND GASTRIN ASSESSMENT
Patients reported between 09:00h and 10:00h following an overnight 
fast. Subjects cleaned their teeth and then an intravenous cannula was 
inserted. Three x 20ml venous blood samples obtained at 15 min intervals 
for fasting gastrin determination. A breath sample was collected for 
baseline 14C-C02 determination. The subject then drank over 5 minutes 
250ml Ensure Plus (Abbott Labs. Ltd., Maidenhead, U.K.) which contains 
300calories/200ml, 12.5g of protein, 40g carbohydrate, lOg fats, and 
vitamins including Vitamin A, Vitamin D, Vitamin K, Vitamin C and 
Vitamin E, pholic acid and Br  B2, Bfi plus elements of sodium, potassium 
and calcium.
Immediately following this they drank 100ml water containing 0.4MBq 
14C-urea. Further 20ml blood samples for serum gastrin were obtained at 
15 min intervals for 90 mins. A further breath sample for 14C 0 2 
determination was obtained at 20 min, 40 min and 100 min following 
administration of the 14C-COr
When the combined gastrin/breath tests were performed at the end of 
the omeprazole treatment periods the omeprazole medication was taken 
that morning two hours prior to commencing the test.
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9.2.4 ENDOSCOPIC EXAMINATION
During each endoscopic examination 3 biopsies were taken from the 
antrum of stomach for histology, CLO-test (Marshall et al 1987) for H. 
pylori and culture for H. pylori. Gastric antral biopsies were taken and 
transported to the laboratory in 0.9% sterile saline, all biopsies were 
cultured within 4 hours.
9.3 COMPLIANCE
Compliance with the omeprazole therapy was assessed by performing 
capsule counts at each visit. Missing >25% of the total tablets over the 
relevant treatment period was considered to be unacceptable compliance. 
In addition, patients were contacted by telephone at regular intervals 
during the study to encourage compliance. Patients were also contacted 7 
days and 24 hours prior to the assessment visits during the omeprazole 
therapy to further ensure compliance.
9.4 ANALYSES
Serum gastrin concentration was measured by radioimmunoassay using 
antibody 198 which detects G17 and G34 with sim ilar affinity  
(Mulholland et al 1993). Fasting gastrin was calculated as the median of 
the 3 samples obtained at 15 min intervals prior to commencing the meal. 
The meal-stimulated gastrin was calculated as the median of the 3 samples 
obtained at +15, +30 and +45 min. This time was chosen as it represented 
the time showing the nominal gastrin response to the meal.
The 14C-urea breath test and culture of H. pylori were performed. The 
gastric antral biopsies were taken and transported to the laboratory in 0.9% 
sterile saline (Veenendaal et al 1993). All biopsies were cultured within 
four hours. The biopsies were homogenised and inoculated onto a blood 
agar base no. 2 (Oxoid) agar plate (Jones et al 1984) containing 10% v/v
112
horse blood and Skirrows selective supplement (Oxoid). The plates were 
incubated for 72 hours at 37°C in a microaerophilic atmosphere (BBL 
Campypak). Typical colonies which were oxidase and urease positive 
were identified as Helicobacter pylori.
The statistical significance of changes following the various treatments 
was assessed by the Wilcoxon paired samples ranking test. The statistical 
significance of differing responses between the H. pylori eradicated and 
non-eradicated groups was assessed.
The study was approved by the West Glasgow Hospitals University 
NHS Trust Ethics Committee.
9.5 RESULTS
Of the thirty-three patients initially recruited, poor compliance with the 
protocol resulted in eight being excluded from the analysis after the one 
month of omeprazole 40mg and eleven after the six months of omeprazole 
20mg.
Of the thirty-three patients recruited, fifteen were randomised to H. 
pylori eradication therapy and thirteen of them were H. pylori negative 
when reassessed four weeks following discontinuation of the therapy. 
Each of those thirteen had a 20 minute 14C-urea breath test value of less 
than 14kg percentage dose/mmol C 02 x 100 a negative antral CLO-test 
and no H. pylori on microscopy or culture of antral biopsies. Both of 
those still positive had a 20 minute 14C-urea breath test value of more than 
362 positive antral CLO-test and positive microscopy and culture of antral 
biopsies. Of the eighteen subjects who received only symptomatic 
therapy, all remained positive for H. pylori one month post-treatment by 
each of the above tests.
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9.5.1 ENDOSCOPIC FINDINGS
Of the thirteen patients in whom H. pylori was subsequently eradicated, 
their endoscopic diagnoses on initial presentation included duodenal 
ulceration in eight, oesophagitis in three and duodenal ulceration plus 
oesophagitis in one and one further patient with duodenal ulcer plus 
pre-pyloric ulcer. The only endoscopic abnormality in those patients at 
one month after triple therapy was mild oesophagitis in one patient. Of 
the two patients in whom the triple therapy failed to eradicate H. pylori, 
one had duodenal ulceration and one had prepyloric ulceration on initial 
presentation, but both showed complete healing one month after triple 
therapy.
Of the eighteen patients who received sym ptom atic therapy, 
endoscopic findings at initial presentation included duodenal ulceration in 
ten, prepyloric ulceration in two, oesophagitis in three, duodenal 
ulceration plus oesophagitis in two and duodenal ulceration plus gastritis 
in one patient. On reassessment, after two months symptomatic therapy 
alone, endoscopic examination showed duodenal ulceration in nine, 
oesophagitis in four, prepyloric ulceration in two, duodenal ulcer and 
gastritis in two and one patient showed no persisting abnormality.
Endoscopic examination was normal in all but one subject after one 
month of omeprazole 40mg per day. This one exception was a patient 
with persisting prepyloric ulceration and who had originally received 
symptomatic therapy. Endoscopic examination was normal in each of the 
subjects reassessed after six months treatment with omeprazole 20mg per 
day.
9.5.2 H. PYLORI ASSESSMENT DURING OMEPRAZOLE THERAPY
Of the thirteen patients who were successfully eradicated of H. pylori 
when examined one month after triple therapy, each had negative antral 
CLO tests and negative antral culture and negative histology for H. pylori
114
when reassessed after one month omeprazole 40mg/day and six months of 
omeprazole 20mg/day.
Of the twenty patients who rem ained H. pylori positive after 
symptomatic (n=18) or triple therapy (n=2), fifteen were reassessed after 
one month omeprazole 40mg per day. At this time point, six had negative 
antral CLO tests and three of these six showed normal antral histology and 
no microscopic evidence of H. pylori. One further patient had a positive 
antral CLO test but had normal histology and no evidence of bacteria on 
microscopy. Eight of the fifteen patients had negative culture of antral 
biopsy.
Of these twenty patients who were H. pylori positive after symptomatic 
or triple therapy, 12 were reassessed after six months of omeprazole 20mg 
per day. Four had both negative antral CLO test and no evidence of H. 
pylori on microscopy of antral biopsy and two of these patients showed 
resolution of antral gastritis. One further patient had no evidence of H.P 
on antral microsocpy. Seven of them were negative for H.P on culture 
(Tables 4,5 and 6).
The 14C-urea breath tests performed 4 weeks after completing the 
omeprazole 20mg were negative in all those initially eradicated of the 
infection by triple therapy and positive in all those who had the 
unsuccessful triple therapy or no triple therapy.
9.5.3 SERUM GASTRIN
On initial presentation prior to treatment with triple/symptomatic 
therapy, the patients in whom H. pylori was subsequently eradicated had 
similar fasting (median = 43ng/l, range 17-226) and meal-stimulated
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PATIENT CLO TEST HISTOLOGY CULTURE
1 Negative Normal Negative
2 »i N N
3 it I t n
4 N N N
5 11 II M
6 M M «
7 N n n
8 II Mild gastritis ii
9 It Mild gastritis i t
TABLE 4: EFFECT OF OMEPRAZOLE ON 40mg FOR ONE MONTH 
ON THE H. PYLORI ERADICATED PATIENTS
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NO. CLO TEST HISTOLOGY CULTURE
1 + Ch. gastritis 
H.P+ve
+
2 + ft +
3 - N -
4 + ft +
5 + ft -
6 - NAD H.P -vc -
7 + Ch. gastritis 
H.P+vc
+
8 - NAD H.P -vc -
9 - n -
10 + Ch. gastritis 
H.P +vc
+
11 + NAD HP -ve -
12 - Ch. gastritis 
H.P+vc
-
13 - w -
14 + Mild gastritis 
H.P-yc
-
15 + Ch. gastritis 
H.P+ve
♦
TABLE 5: EFFECT OF OMEPRAZOLE 40mcFOR FOUR WEEKS ON THE
H. PYLORI NON-ERADICATED PATIENTS
12
3
4
5
6
7
8
9
10
11
12
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CLO TEST HISTOLOGY CULTURE
Ch. gastritis H.P. -ve
Ch. gastritis H.P. -ve
Ch. gastritis H.P. +ve
Ch. gastritis H.P. +ve
H.P. -ve
Ch. gastritis H.P. -ve
H.P. +ve
NAD H.P -ve H P  -ve
NAD H.P -ve H P -ve
Ch. gastritis H P -ve
HP+ve
//./> +ve 
H.P. +ve 
H.P. -ve 
H P  +ve
EFFECT OF OMEPRAZOLE 20mg FOR SEC MONTHS ON 
H. PYLORI NON-ERADICATED PATIENTS
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serum gastrin concentrations (median = 93, range 31-286) compared with 
the patients in whom the infection was not subsequently eradicated 
(fasting median = 38, range 19-114; meal-stimulated median = 75, range 
24-162).
On re-assessment at V12 following failed triple therapy or symptomatic 
therapy there was no change in fasting or meal-stimulated gastrin 
concentrations (Fig. 22). In contrast, the patients in whom H. pylori was 
eradicated showed a 36% median fall in fasting gastrin and 48% median 
fall in meal-stimulated gastrin (p<0.01 for each) (Fig. 23).
In the patients who were not eradicated of H. pylori their median 
fasting gastrin at the end of the one month course of 40mg omeprazole 
was 145% higher than that immediately prior to commencing the proton 
pump inhibitor (p < 0.001) and their meal-stimulated gastrin 43% higher 
(p<0.005) (Fig. 24). In these subjects their median fasting gastrin at the 
end of 6 months 20mg omeprazole was 78% higher than that immediately 
prior to omeprazole (p<0.005) though their median meal-stimulated 
gastrin was only 2% higher which was not statistically significant 
(Fig. 25).
In the patients eradicated of H. pylori their median fasting gastrin at the 
end of the one month course of 40mg omeprazole was 38% higher than 
that immediately prior to commencing the proton pump inhibitor (p<0.05) 
and their meal stimulated gastrin was 112% higher (p<0.02) (Fig. 
26). In these subjects their median fasting gastrin at the end of the 6 
months of 20mg omeprazole was 31% higher than that immediately prior 
to starting omeprazole though their meal-stimulated gastrin was only 6% 
higher which was not statistically significant (Fig. 27).
When taking the gastrin values immediately prior to omeprazole as the 
starting values the change with respect to both fasting and meal-stimulated
250
240
230
220
210
200
190
180
170
160
150
140
130
120
110
100
90
80
70
60
50
40
30
20
10
0
Fasting Meal Stimulated
 , , 1 1------
Initial Post Initial Post
Assessment Treatment Assessment Treatment
I meal-stimulated gastrin concentrations on initial assessment and 
eks of symptomatic treatment (•) or failed anti-//. pylori 
)-
120
Fasting Meal Stimulated
180
170
160
150
140
130
120-
^  110-  
 i
&  100-1 c
CO
CO
O
90- 
80- 
70- 
60 
50-i 
40 
30-i 
20 
10-1 
0
286,
Initial 
Assessment
Post 
H.Pylori 
Eradication
Initial 
Assessment
Post 
H.Pylori 
Eradication
Figure 22
Fasting and meal-stimulated gastrin concentrations on initial assessment and 
1 month alter completing successful anti-//, pylori therapy.
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proton pump inhibitor.
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Fasting and meal-stimulated gastrin concentrations before commencing any 
omeprazole and after 6 months of omeprazole 20mg/day in the patients who
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gastrin in response to omeprazole was similar in the H. pylori eradicated 
and H. pylori non-eradicated patients.
Compared to their values at the initial assessment the median fasting 
gastrin concentrations in those not eradicated of H. pylori was increased 
by 100% after 1 month omeprazole 40mg and by 68% after 6 months 
omeprazole 20mg (p<0.005 for both) (Fig. 28). In contrast, in the patients 
who were eradicated of H. pylori pre-omeprazole their fasting gastrin 
concentrations after both one month 40mg omeprazole and 6 months 
20mg omeprazole were similar to those at initial assessment (Fig. 29).
In the patients not eradicated of H. pylori their median postprandial 
gastrin concentration after one month omeprazole 40mg was 16% higher 
than that on initial presentation (p<0.05), but their value after 20mg for 6 
months was similar to that on initial presentation (Fig. 30). In the patients 
eradicated of H. pylori pre-omeprazole their median postprandial gastrin 
concentration after 1 month omeprazole 40mg was similar to that on initial 
presentation, however their median value after 6 months omeprazole 20mg 
was 52% lower than on initial presentation (Fig. 31).
9.5.4 14C UREA BREATH TEST
The results for the 14C-urea breath test in the two groups, H. pylori 
positive and H. pylori negative as shown in Figures 32 and 33. The 40mg 
omeprazole dose lowered 14C-urea breath test value in the H. pylori 
positive subjects and increased it in the H. pylori negative subjects, 
resulting in a loss of statistical difference between the two groups. The 
effect was less marked on the 20mg omeprazole for 6 months and resolved 
within four weeks of stopping the proton pump inhibitor. The 14C-urea 
breath test nearly reversed to the initial value after four weeks without the 
proton pump inhibitor (Fig. 34).
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H. pylori infection prior to commencing the proton pump inhibitor.
H.Pylori eradicated
Pre-omeprazole
H.Pylori eradicated
Pre-omeprazole
230-l
220-
210-
200-
90-
80-
70-
60-
50-
40-
30-
20-
c
CO
CO
(D
E3
k .©
CO
o>c
10-
00-
90-
%
COu.
70-
30-
20-
10-
Omeprazole OmeprazoleInitial Initial
Assessment 40mg for 
1 month
Assessment 20mgfor 
6 months
Figure 29
Fasting serum gastrin on initial presentation and after 1 month omeprazole 
40g/day 6 months omeprazole 20mg/day in those eradicated of their H. pylori 
prior to commencing the proton pump inhibitor.
M
ea
l - 
St
im
ul
ate
d 
Ga
str
in 
Le
ve
l 
(n
g/
L)
128
240 i  
230-  
2 2 0 -  
2 1 0 -  
2 0 0 -  
190- 
180- 
170- 
160- 
150- 
140- 
130- 
1 2 0 -  
1 1 0 -  
1 0 0 -  
90-  
80-  
70-  
60-  
50-  
40-  
30-  
20 -  
10 -
H.Pylori not eradicated
Pre-omeprazole
H.Pylori not eradicated
Pre-omeprazole
0 ------------ r
Initial 
Assessment
F ig u re d
Omeprazole 
40mg for 
1 month
Initial 
Assessment
Omeprazole 
20mg for 
6 months
M eal-stim ulated gastrin on initial presentation and after 1 month
omeprazole 40g/day and 6 months omeprazole 20mg/day in those not
eradicated of H. pylori prior to commencing the proton pump inhibitor.
129
cfcc
CO
CO
CD
1
IS3e
o5
co
©
2
290 
280 H 
270 J 
260-1 
250 
240 
230 
220 
210 
200 
190 
180 
170 
160 
150 
140 
130- 
120-  
110-  
100-  
90. 
80 
70 
60<1 
50 
*40- 
30- 
20 -  
10-  
0
H.Pylori eradicated
Pre-omeprazole
H.Pylori eradicated
Pre-omeprazole
Initial 
Assessment
Omeprazole 
40mg for 
1 month
Initial 
Assessment
Omeprazole 
20mg for 
6 months
Figure 31
M eal-stim ulated gastrin on in itia l presentation and after 1 month
omeprazole 40mg/day and 6 months o f omeprazole 20mg/day in those
eradicated of H. pylori prior to commencing the proton pump inhibitor.
130
•  Pre Omeprazole
o  Omeprazole 40mg 
for 1 month 
■ Omeprazole 20mg 
for 6 months 
□ Off Omeprazole 
for 1 month
220
O  200 o
X
180-
O
o
E 160- 
E 
0)
o  140- 
*0
120-
<D
To 100- 
>
co
<D
80-
co
CD
.Q
CO
CDw
60-
20-
100
Time (mins)
Figure 32
The effect of omeprazole on 14C-urea breath test in eradicated patients with 
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The effect of omeprazole on l4C-urea breath test in the non-eradicated 
patients with H. pylori.
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9.6 DISCUSSION
Proton pump inhibitor drugs and H. pylori infection are both important 
causes of hypergastrinaemia (Koop et al 1990, Chittajallu et al 1992). Due 
to the high prevalence of H. pylori infection, a considerable proportion of 
subjects prescribed long term proton pump inhibitor therapy will be H. 
pylori positive and there is therefore interest in the combined effects of the 
two on serum gastrin. The present study indicates that the percentage 
increase in gastrin induced by proton pump inhibitors at least as high in H. 
pylori positive compared to negative subjects. Consequently patients who 
have a higher gastrin value prior to commencing omeprazole to H. pylori 
infection also have a higher gastrin during omeprazole therapy. This 
observation is consistent with our previous study with 5 days treatment 
with another proton pump inhibitor pantoprazole (McColl et al 1992). Our 
findings are also consistent with studies prior to the recognition of H,. 
pylori which noted that subjects with higher pre-treatment gastrin also had 
higher values on omeprazole (Koop et al 1990, Jansen et al 1990). The 
present study also demonstrates that eradicating H. pylori infection prior to 
commencing the proton pump inhibitor is an effective means of reducing 
the hypergastrinaemia on treatment.
Though both H. pylori infection and proton pump inhibitor therapy 
cause hypergastrinaemia, the present studies indicate that they differ in the 
degree to which they raise fasting and m eal-stim ulated gastrin 
concentrations. Eradication of H. pylori infection was associated with a 
more profound fall in meal-stimulated than fasting gastrin concentrations 
and this is consistent with many previous studies showing that the 
infection predominantly increases meal-stimulated gastrin concentrations 
(McColl et al 1991). In contrast, in the present study, the proton pump 
inhibitor therapy resulted in a greater percentage rise in fasting gastrin
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levels than meal-stimulated levels and this was apparent in both H. pylori 
positive and H. pylori eradicated subjects. The relative efficacy of 
omeprazole and H. pylori in raising meal-stimulated gastrin levels 
explains how the combination of omeprazole + H. pylori eradication 
actually lowered meal-stimulated gastrin, the H. pylori eradication 
gastrin-lowering effect being greater than the omeprazole gastrin-elevating 
effect. The reason for omeprazole having a more marked effect on fasting 
than meal-stimulated gastrin may be explained by the difference in fasting 
and fed intragastric pH. Fasting pH is usually considerably less than 3 and 
at this intragastric acidity gastrin release is inhibited (Penston et al 1990). 
Omeprazole usually raises fasting pH above pH4 thus disinhibiting gastrin 
release (Lind et al 1991). Following a meal intragastric pH may already be 
above pH4 due to the buffering effect of the food and thus gastrin release 
will already be disinhibited. Consequently, any additional increase in pH 
due to omeprazole may have relatively little effect on the post meal gastrin 
level.
The resultant effect on gastrin of proton pump inhibitor therapy plus H. 
pylori infection will depend upon the mechanism by which each 
independently produces hypergastrinaemia. As stated above, the former is 
thought to cause hypergastrinaemia by removing the inhibition of gastrin 
release exerted by low intragastric pH (Banerjee et al 1995, Lind et al 
1991). Hypergastrinaemia associated with H. pylori infection is thought to 
be secondary to depletion of antral somatostatin which exerts paracrine 
inhibitory control on gastrin release by the antral G cells (Odum et al 
1994, Kaneko et al 1992, Moss et al 1992). Somatostatin is largely 
responsible for mediating the inhibition of gastrin release exerted by low 
intragastric acid pH (Lucey et al 1989) and impaired inhibition of gastrin 
release at low pH occurs in the presence of H. pylori infection (Tarnasky 
et al 1993). Thus, both H. pylori infection and acid inhibitory therapy are
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thought to cause hypergastrinaemia by disrupting the inhibition of gastrin 
release normally exerted by gastric acid. If that is the case, then one might 
expect that acid inhibitory therapy would result in a greater percentage 
increase in gastrin in H. pylori negative subjects who start with their 
gastrin normally suppressed by acid than in H. pylori positive subjects in 
whom the infection has already disinhibited gastrin release. However, in 
our present study we found that the percentage increase in gastrin during 
omeprazole therapy was at least as great in the presence versus absence of 
H. pylori infection. This disparity may be explained by additional factors 
influencing the combined effect of H. pylori plus omeprazole on serum 
gastrin.
The first of these additional factors is the recent observation that the 
degree of elevation of intragastric pH caused by omeprazole is dependent 
upon H. pylori status (Verdu et al 1995, Verdu et al 1995). Verdu et al 
observed that omeprazole 20mg/day raised daytime pH from 1.3 to 5.4 in 
H. pylori positive subjects but from 1.4 to only 2.9 in H. pylori negative 
subjects. Likewise, it raised nighttime pH from 1.1 to 4.7 in H. pylori 
positive subjects, but from 1.1 to only 1.9 in H. pylori negative subjects. 
The mechanism by which H. pylori infection accentuates the antacid 
effects of omeprazole is unclear. However, it is known that there is an 
increase in severity of corpus gastritis (Logan et al 1995) in H. pylori 
subjects during omeprazole therapy and this may impair the acid secreting 
capacity of the oxyntic mucosa. Whatever its mechanism, this accentuated 
pH elevation produced by omeprazole in H. pylori positive subjects will 
result in more complete disinhibitor of gastrin release.
Recent studies indicate that there is progression of corpus atrophy 
during long term proton pump inhibitor therapy in H. pylori positive 
subjects which does not occur in uninfected subjects (Kuipers et al 1994, 
Kuipers et al 1995). The development of atrophy during longer term
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omeprazole treatment will further reduce intragastric acidity and 
consequently further increase gastrin levels in H. pylori positive subjects.
Another factor influencing the combined effect of omeprazole and H. 
pylori on gastrin is the observation that omeprazole treatment reduces the 
density of the infection present in the gastrin-producing antral region of 
the stomach (Logan et al 1995, Weil et al 1991, Hui et al 1991). In the 
present study, H. pylori infection was cleared from the antral mucosa in 
33% of the infected subjects. This suppression of H. pylori in the antral 
region by omeprazole will tend to reduce hypergastrinaemia by reducing 
the H. pylori induced hypergastrinaemia. This may explain the variations 
in degree of hypergastrinaemia seen in H. pylori positive subjects during 
omeprazole.
Though the interacting mechanisms involved in the combined effects of 
H. pylori and omeprazole on gastrin are complex, the present study clearly 
shows that eradicating H. pylori effectively reduces gastrin levels during 
subsequent omeprazole therapy. In view of the uncertainty about some of 
the possible longterm sequelae of hypergastrinaemia in man, it may be 
appropriate to screen for H. pylori prior to commencing longterm proton 
pump inhibitory therapy and eradicate it when present. A similar policy 
has recently been advocated in order to prevent the development of corpus 
atrophy during longterm proton pump inhibitory therapy (Kuipers et al 
1994; Kuipers et al 1995). Whether such a policy will also reduce the 
clinical efficacy of the proton pump inhibitor due to reducing its pH 
elevating effect is unknown.
CHAPTER TEN 
SUMMARY AND CONCLUSIONS
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In this thesis we have studied the effect of H. pylori infection on serum 
gastrin and the possible role of bacterial ammonia production producing 
hypergastrinaemia. We have also studied the interacting effects of H. pylori 
infection and proton pump inhibitor therapy on serum gastrin concentrations.
In Chapter 4 it was noted that H. pylori infection increased both basal 
and meal-stimulated serum gastrin concentrations. Eradication of the infection 
produced resolution of the hypergastrinaemia. The increased serum gastrin 
concentrations associated with H. pylori infection in the D.U. patient was 
accompanied by a less marked rise in intragastric pH in response to the buffering 
effect of a meal. This is consistent with the hypergastrinaemia producing 
increased gastric acid secretion in response to the meal. However, it was 
appreciated that the measurement of intragastric pH was a relatively insensitive 
means of measuring changes in acid secretion due to H. pylori induced 
hypergastrinaemia and tests of actual gastric acid secretion would be more 
appropriate.
We then proceeded to investigate the mechanism of the 
hypergastrinaemia induced by H. pylori infection. A possible mechanism was 
that the ammonia produced by H. pylori urease activity was increasing antral 
surface pH and thus inhibiting the physiological suppression of gastrin release 
exerted by low intragastric pH. We approached this hypothesis by first of all 
examining in Chapter 5 the effect of H. pylori on gastric juice, urea and ammonia 
concentrations. This showed a marked lowering of urea concentration and 
marked elevation of ammonia concentrations in subjects with H. pylori infection 
compared with uninfected controls. This work also suggested that the 
measurement of the ratio of urea to ammonia in gastric juice might provide a 
rapid means of diagnosing the presence of the infection during the endoscopic 
examination.
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We then proceeded to investigate the relationship of H. pylori ammonia 
production and serum gastrin. In Chapter 6, we examined patients with uraemia 
due to chronic renal failure. Such patients with H. pylori infection had markedly 
increased gastric juice ammonia concentrations compared to uninfected uraemic 
patients. This allowed us to determine whether very high levels of ammonia 
production in these patients was associated with more marked hypergastrinaemia. 
However, we were unable to show any association between the degree of H. 
pylori ammonia production and the degree of hypergastrinaemia.
We proceeded to further investigate the relationship between H. pylori 
ammonia production and serum gastrin in Chapter 7 by inhibiting H. pylori 
ammonia production and determining whether this produced a fall in serum 
gastrin. This was done using the urease inhibitor acetohydroxamic acid. The use 
of this drug markedly inhibited H. pylori ammonia production but this was not 
associated with any change in serum gastrin.
We then proceeded to further test the hypothesis that H. pylori was 
raising serum gastrin as a result of the bacterium elevating antral surface pH. If 
this hypothesis were true, then elevation of intragastric pH by proton pump 
inhibitor therapy should produce a smaller percentage increase in serum gastrin in 
H. pylori positive subjects than in H. pylori negative subjects. This would be the 
case because H. pylori infection would already have interrupted the inhibition of 
gastrin due to intragastric acid and therefore removing intragastric acid would 
have little effect. In contrast, in those without H. pylori infection, their gastrin 
would be suppressed by the intragastric acid and removing it by proton pump 
inhibitory therapy would therefore cause a significant rise in gastrin. We initially 
tested this hypothesis in Chapter 8 using one weeks treatment with a proton pump 
inhibitor and found that the rise in gastrin was similar in those with and without 
H. pylori infection.
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We then proceeded to a longer term study in Chapter 9 in which we 
examined the effect of proton pump inhibitors on serum gastrin in patients with H. 
pylori infection and another group of patients in whom we have rendered H. 
pylori negative by eradication therapy. We studied serum gastrin in these patients 
at initial presentation after treatment with eradication therapy or placebo, and then 
after treatment with the proton pump inhibitor for one month and for six months. 
We found that the percentage rise in serum gastrin during the treatment with the 
omeprazole was similar in those who are H. pylori positive compared to those 
who are H. pylori eradicated. This again failed to provide support for the 
hypergastrinaemia being due to H. pylori induced elevation of antral surface pH.
One clinically relevant observation from the above study is that 
eradication of H. pylori infection is an effective means of reducing the degree of 
hypergastrinaemia induced by long term proton pump inhibitor therapy. There is 
concern that hypergastrinaemia on such therapy may lead to ECL-cell hyperplasia 
and even carcinoid tum ours and consequently the ability  to lim it the 
hypergastrinaemia by eradicating H. pylori infection seems indicated. We would 
therefore recommend that patients requiring long term proton pump inhibitory 
therapy should be tested for H. pylori infection and have the infection eradicated 
if present
Overall studies have found little support for the hypothesis that H. 
pylori induced hypergastrinaemia is related to bacterial ammonia production. 
Other mechanisms need to be considered including the effect of cytokines and 
other inflammatory mediators induced by the bacterial infection.
In the course of these studies we have made two observations with 
important clinical implications. The first is the finding that eradicating H. pylori 
infection is effective in lowering serum gastrin concentration and, in particular, in 
reducing the marked hypergastrinaemia associated with long term proton pump 
inhibitor therapy. In view of the fact that hypergastrinaemia induces ECL cell
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hyperplasia, it would seem appropriate to eradicate H. pylori prior to long-term 
proton pump inhibitor therapy. The second important observation is that 
omeprazole markedly interferes with the accuracy of most H. pylori diagnostic 
tests. This is due to temporary suppression of the infection without true 
eradication. An increasing number of dyspeptic patients are receiving omeprazole 
and this will be confusing the results of their H. pylori tests.
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